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EDITORIAL
Having been born in the antibiotic era – as was
anyone born since penicillin entered the world stage 
in 1944–45 – I always assumed that bacterial infections
were an irritation but manageable. As a child, I was
fed antibiotics in a pink syrup to cure earache; as 
an adult, an IV drip poured antibiotics into my veins 
to defeat tonsillitis. Antibiotics have been taken for
granted, always there, ready to counter infections 
of any part of the body.
Yet in the last few years, the doubts have started to
creep in. Might bacteria be regaining the upper hand?
Headlines trumpeting ‘MRSA is winning’ and ‘New
lethal superbugs’ have become ever more frequent, 
as have reports of how bacteria have found ways 
to bypass, break down or just ignore our antibiotics.
Microbiologists may wince at the term ‘superbug’,
but it has become shorthand for infections of resistant
bacteria caught in hospitals – which dominate the
headlines – or in the community. Both are on the rise,
while the flow of new drugs from the pharmaceutical
industry has slowed to a trickle.
This Wellcome Focus examines how science is
responding to this challenge. Researchers are tackling
bacteria from many different angles: how antibiotics
work and the mechanisms bacteria use to resist the
drugs; how our use of antibiotics, often excessive and
uncontrolled, has driven the rise and spread of resistant
strains; how these strains can be identified, tracked and
their spread stopped; and how new drugs that can kill
resistant infections are being developed. As the articles
in this issue describe, progress is being made in all 
of these areas although there is still a lot to learn.
While Wellcome Focus is looking at antibiotics and
bacteria, resistance as a phenomenon is found in
many other organisms. For example, widespread
resistance in the malaria parasite has rendered the
cheap and effective drug chloroquine almost useless.
Resistance in the human immunodeficiency virus 
(HIV) threatens the usefulness of antiretrovirals.
Attack any organism, it seems, and nature will almost
always come up with a plan B to help survival. Humans
have won notable battles in the war against infection –
and antibiotics are still powerful weapons – but nature
has evolution on its side, and the war against bacterial
diseases is by no means over.
Dr Giles Newton, Science Editor
Introducing Wellcome Focus…
This is the first issue of a new publication, 
Wellcome Focus, which we intend to publish once 
a year. Our objective is to provide accessible, 
up-to-date and reliable guides to important and
topical areas of medical science.
Research seems to progress at ever faster rates, 
and even specialists struggle to keep up with the
deluge of information constantly being generated.
This information ends up in the primary literature, 
but that is a daunting starting point for anyone who
does not already have a detailed understanding of 
an area. On the other hand, material for general
audiences often focuses on healthcare delivery 
– but it can take a long time for the impact of new
discoveries to be felt in medical practice.
With Wellcome Focus, we hope to fill that gap. 
We hope to provide an overview of an area of
medicine and key areas of research within it. Our
belief is that this will be of value to a wide range 
of people, including: professional scientists reading
outside their own area; healthcare workers of all
descriptions; teachers looking for authoritative and
topical resources for their students; other people 
with a professional interest in science and medicine;
and, not least, members of the general public who 
are looking for a balanced and accessible insight 
into key issues in human health.
Our experience with Wellcome News Supplements –
such as last year’s, Talking Heads: Cognitive
behavioural therapy comes of age – suggests that
there is an appetite for this kind of publication. 
But if you feel there are other ways in which 
Wellcome Focus could better meet your needs, 
do please let us know.
Introducing the Wellcome Trust…
The Wellcome Trust is an independent research-
funding charity, established under the will of Sir Henry
Wellcome in 1936. It is funded from a private
endowment, which is managed with long-term
stability and growth in mind. Its mission is to foster
and promote research with the aim of improving
human and animal health.
www.wellcome.ac.uk
Wellcome Focus provides an overview of an area of medicine and
key areas of research within it, through a mix of review articles,
personal comment and research reports. It aims to provide
scientists, healthcare workers, teachers, people with a professional
interest in science and medicine, and interested members of the
general public with a balanced and accessible insight into key
issues in human health. It is available free (see inside back cover
for ordering details).
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Fighting back
Twenty years ago, if an antibiotic became less useful
because of resistance, there was always another drug
coming along to solve the problem. This supply line
has slowed markedly: it is now much harder to find
new drugs (the ‘easy’ ones have been found) and
many pharmaceutical companies have focused their
efforts on more commercially rewarding markets. 
New potential targets for drugs have been identified
from the sequencing of the genomes of bacterial
pathogens – many of which have been deciphered –
but it has taken much longer than expected to bring
such drugs to market.
Improvements in hygiene, vaccines to boost our
immune defences and, in the future, therapies based
on bacteriophages (bacteria-killing viruses) can all have
a role in slowing the spread of resistance. Even so,
antibiotics remain our key drugs, and measures to
preserve their utility have become a priority. Their use
as growth promoters in food animals is being reduced,
and prescribing for humans now aims to be more
tailored and less frequent; in the UK, for example, total
community prescribing has fallen by a quarter since
the mid-1990s.
But at least part of the responsibility falls on us as
consumers. Expecting instant cures, we pressurise
GPs to prescribe antibiotics for inappropriate illnesses
such as viral respiratory tract infections. As soon 
as we feel better, we hoard spare tablets in the
medicine cabinet, sharing them with friends and
family. Antibiotics are precious: we need to appreciate
them more and be more thoughtful about their use.
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The last century saw a stunning swing in our fortunes
against infectious bacteria: antibiotics, vaccination and
clean water supplies slashed death rates, particularly 
in developed countries. With the rise of resistance to
antibiotics in many species of bacterium, the pendulum
seems to be swinging back. 
This is not a new problem: the release of an antibiotic
has usually been followed – sometimes quite soon
after – by the appearance of bacteria oblivious to 
the new drug’s effects. Indeed, even Sir Alexander
Fleming pointed out in his 1945 Nobel Prize speech:
“It is not difficult to make microbes resistant to
penicillin in the laboratory by exposing them to
concentrations not sufficient to kill them, and the
same thing has occasionally happened in the body.”
Life with bacteria
We live with bacteria all the time. They live on surfaces,
on our skin, in our mouths, up our noses and in our
intestines. By and large, we get along fine. One-third 
of the world’s population carries Staphylococcus aureus
in the nose all the time and another third carries it now
and again – and we have no idea it is there. Billions 
of bacteria, including Escherichia coli, live in our lower
intestines. Indeed, this normal bacterial ‘flora’ is
useful, competing with and limiting the expansion 
of dangerous bacteria.
Antibiotics and vaccines also keep dangerous
bacteria at bay. But humans have used antibiotics 
on an epic scale; in evolutionary terms, the selective
pressures have been immense. Genetic changes
that can help a bacterium resist a drug are rare, 
but bacteria reproduce so fast that they can
disregard casualties. If a strain does pick up 
a mutation, or acquires a resistance mechanism 
from another, it will have a definite edge over its
susceptible peers in the presence of the antibiotic.
It is indeed survival of the fittest.
Resistance at large
That resistance should arise is no surprise: it is just
nature’s way. What is surprising is how fast some
strains of resistant bacterium can spread from 
person to person, from hospital to hospital and, 
aided by the increase in international travel, from
country to country.
Methicillin-resistant S. aureus (MRSA) has become
synonymous with hospital-acquired infections, even
though these bacteria account for only a proportion 
of the infections that afflict about one in ten hospitalised
patients. Hospitals are perfect for such ‘opportunistic
pathogens’: they are full of sick people with depressed
immune systems; large amounts of antibiotics are
dispensed; and catheters and surgery allow the
bacteria to invade the body. Fortunately, few infections
– whether of MRSA or other bacteria – are untreatable
as we still have back-up drugs that work in most
cases. Even so, patients have their stays prolonged
and require additional diagnostic and therapeutic
treatments; the additional costs are estimated 
to exceed £1 billion every year in the UK alone.
In the community, resistance is found in bacteria that
cause pneumonia, earache, urinary tract infections,
sexually transmitted infections and so on. Such
resistant bacteria are a huge problem in developing
countries, which still face an alarming death toll from
bacterial infections: pneumonia and meningitis caused
by Streptococcus pneumoniae are estimated to kill 
1.6 million people every year and doctors are extremely
worried by increasing rates of multidrug-resistant
Mycobacterium tuberculosis. These countries may 
not be able to afford alternative drugs if cheap, 
first-line antibiotics become useless.
Antibiotics and bacterial resistance
Sixty years ago, the arrival of antibiotics seemed the answer to the bacterial
diseases that have plagued humans through history. But are bacteria regaining
the upper hand?
AN UNWINNABLE WAR?
Humans have used antibiotics 
on an epic scale
«
«
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Today, it is often forgotten that the challenge of
antibiotic resistance was raised immediately the 
drugs were introduced. From the late 1940s, micro-
biologists and policy makers responded with attempts
to restrict use through the prescription system and by
the development of more robust drugs. Even then, the
experts saw their measures as only partial solutions to
a problem that was both medical and social. Yet in an
age in which authority was increasingly distrusted, the
warnings of pessimistic prophets were discounted by
grateful patients and hurried practitioners alike. Only 
in the late 1990s was the emergence of resistant 
bacteria widely accepted as a global threat to be 
taken seriously.
Until the 1930s, there had been no chemical
treatment available to fight bacterial infections in
general. Prevention was the main means of protecting
patients, and an obsession with the threat of germs
and the moral responsibility to avoid infection were
deeply instilled in Western cultures. At the same time,
there were repeated hopes for a wonder drug. Louis
Pasteur’s pupil Paul Vuillemin coined the term
‘antibiosis’ in 1889 to mean a process by which life
could be used to destroy life. The word ‘antibiotic’ 
did not follow immediately, but the drug pyocyanase,
a weakly effective antibiotic, was marketed from the
late 19th century into the 1930s. Early in the 1920s,
there was excitement about the potential of the newly
identified phage viruses to attack bacteria on human-
kind’s behalf – remembered in Sinclair Lewis’s 
novel Arrowsmith.
The discovery of an antibacterial factor in the exudate
of the Penicillium mould by Alexander Fleming at 
St Mary’s Hospital in 1928 was therefore not totally
unexpected. Nor was it medically revolutionary. 
At first, it seemed impossible to extract the active
compound intact from the yellow liquid produced 
by the mould, but two new developments in the late
1930s engendered more enthusiasm for the antibiotic
approach to medicine. The sulfonamide drugs offered
cures for a wide range of bacterial infections, 
and the Rockefeller Institute scientist Rene Dubos
managed to extract a powerful antibiotic that he called
tyrothricine from a soil mould, and later refined this 
to gramicidine and tyrocidine (although these could 
not be used internally).
Moreover, new chemical techniques and greater 
interest in natural chemicals such as proteins brought
the problems of separating penicillin to the centre of
pure science. It was scientific opportunity, not medical
aspiration, that initially attracted the attention of the 
biochemist Ernst Chain and his boss, Howard Florey, 
at Oxford University to this challenge. Using the new
technique of freeze-drying, Chain succeeded in 
separating penicillin and then showed that it did 
not harm mice. 
With the intensification of war, medical implications
replaced scientific curiosity as a driver for further 
work, and Florey put together a team of chemists,
microbiologists and clinical scientists that tested
penicillin on human patients during 1941. Yet it was
clear that neither they nor British industry had the
capacity to produce large quantities of penicillin, 
and the world centres of fermentation expertise were
inaccessible in Nazi-occupied Europe. In desperation,
Florey and his colleague Norman Heatley sought the
help of colleagues in the USA. There, with much
greater resources of fermentation experience and
finance, and drawing on the advances made by the 
US Department of Agriculture research laboratory in
Peoria, Illinois, a few companies such as Pfizer and
Merck managed to develop mass-produced penicillin.
By late 1943, the technology for mass production 
had been developed and by D-Day in June 1944, 
there was enough penicillin for all troops.
The history of antibiotics
Antibiotics transformed medicine: many infections could be cured quickly,
and death rates fell. Attitudes to medicine and illness also changed, and
patients’ expectations of rapid cures rose dramatically. By Robert Bud.
THE MEDICINE CHEST
Antibiosis: life could be used 
to destroy life.
«
«
Also in the early 1960s came the emergence of the
cephalosporins (related to the penicillins) and another
new family of antibacterial drugs (strictly not antibiotics,
as they were totally synthetic) best known through 
the drug Cipro – later famously resorted to in the 2001
anthrax scare. However, this was also the end of the
great period of antibiotic development.
By the late 1990s, there was great worry that while
many variants of older drugs had been produced,
new families of antibiotics were not being found. The
promise of molecular biology through the sequencing
of bacterial genomes and the design of chemicals
designed to attack their weak points had not yet borne
fruit by the early 21st century. Vulnerable strains 
of bacterium were replaced by resistant strains. 
In any case, the development of new antibiotics taken
for short periods, often by patients with minor, self-
limiting conditions, was not the principal concern 
of pharmaceutical companies more focused upon 
the challenges and opportunities of treating chronic
conditions. Instead, the focus of the fight against
resistance has been on managing the use of antibiotics
and on preventing the selection of resistant strains.
Robert Bud is Principal Curator of Medicine at the Science
Museum, London, UK. He is an honorary senior research fellow 
in the Department of Science and Technology Studies at University
College London, an honorary research fellow in the Department 
of History, Classics and Archaeology at Birkbeck College and an
associated scholar at the Department of History and Philosophy 
of Science at the University of Cambridge. His book on the 
history of penicillin is currently in press.
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The end of the great period 
of antibiotic development.
«
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Meanwhile, at Rutgers University in New Brunswick,
New Jersey, the achievement of Rene Dubos had
encouraged studies of soil-derived actinomycetes,
yielding a host of new drugs. In 1941, the professor 
of agricultural microbiology Selman Waksman coined
the term ‘antibiotic’. He was emphatic that this type 
of antibacterial drug was necessarily derived from
living organisms. Within the space of a few years,
Waksman’s students separated actinomycin,
neomycin and, above all, streptomycin – the first 
drug to have a proven effect on tuberculosis.
Industry took up the challenge of finding active
moulds, testing the chemicals they produced and
mass producing successful drugs. Parke Davis, 
a long-established firm that had been marginal 
to the penicillin enterprise, extracted what came to 
be known as chloramphenicol from rotten vegetable
remains sent from Venezuela in 1946. At about the
same time, Lederle Laboratories extracted aureomycin
from a soil actinomycete. Pfizer, which had begun as 
a chemical company making drugs for retail-oriented
pharmaceutical firms but then found that these firms
were now manufacturing in their own right, began to
seek drugs it could market itself. The first such product
was terramycin, extracted from an actinomycete found
in soil near its plant in New Jersey.
Chloramphenicol, aureomycin and terramycin differed
from the first-generation antibiotics in that they attacked
a wide range of bacteria, whereas their predecessors,
penicillin and streptomycin, had been effective in
general against only Gram-positive and Gram-negative
bacteria respectively. The greatest of the early broad-
spectrum antibiotics was developed by a Pfizer
chemist, Lloyd H Conover, who realised that terramycin
and aureomycin had similar structures: they shared 
a core that he called tetracycline. The price of penicillin,
which could not be patented, was falling precipitately,
but such new drugs, which could be patented and
whose price held up, became an attractive product 
for companies. 
The new antibiotics had enormous consequences for
both doctors and patients. Certain terrifying infectious
diseases such as rheumatic fever, syphilis, pneumonia
and tuberculosis, and unpleasant skin conditions such
as carbuncles, became easily treatable and their 
disappearance seemed predestined. Surgeons could
risk more dangerous operations and the use of drugs
that compromised immune systems. Patients who 
had once turned to many kinds of alternative medicine, 
or refused treatment, now entrusted themselves to
antibiotics. The clouds of moral disapproval of infection
were dispelled.
Animals benefited too. From 1943, veterinarians
experimented with the use of penicillin to treat
sickness, but within a few years the emphasis 
of agricultural aspirations moved to the use of low
dosages to speed the growth of healthy animals –
young pigs and poultry seemed to benefit in particular.
Yet worries that resistant bacteria would breed in
animals and spread to humans led, in Britain, to the
Swann Committee report of 1969 and subsequent
legislative controls. The significance of the link between
animal uses and bacterial resistance in humans has,
however, been contested to the present day.
Medical uses on human patients were harder to 
limit – even though, from the 1940s, fears that public
enthusiasm would promote the selection of resistant
strains did lead to some constraints. In Britain, the
Penicillin Act of 1948 was explicitly intended to, for 
the first time, limit through prescription the public’s
access to a drug that was not a poison. Nonetheless,
during the 1950s, a penicillin-resistant strain of
Staphylococcus aureus termed 80/81 infected 
hospitals and maternity wards across the world.
Newborn babies in hospital crèches were infected,
post-operative infections proved common, and 
blame was cast on weaknesses of hospital cleaning 
in a culture of increasing dependence on antibiotics 
and changing nursing practices.
One response to the concern about resistance was 
the development of new antibiotics. Erythromycin and
vancomycin were developed by Eli Lilly in the 1950s
and tended to be reserved for cases in which bacteria
had proved resistant to other antibiotics. Scientists at
Beecham led the way in producing the core of penicillin
(called beta-lactam) and then making new synthetic
variants of penicillin. Some of these, such as ampicillin
(1961) and the later amoxicillin, were broad-spectrum
like tetracycline. 
Before even ampicillin, however, in 1960 Beecham and
Bristol brought out meticillin (methicillin), which could
not be destroyed by the beta-lactamase enzyme
produced by S. aureus. Almost immediately, cases of
methicillin-resistant S. aureus (MRSA) were discovered,
although for many years their number was low.
Meanwhile, the new drug seemed the solution to the
threat of S. aureus. Famously, the life of the actress
Elizabeth Taylor was rescued after she was treated 
for staph pneumonia during the shooting of the film
Cleopatra. In part because of the the new drug, the
80/81 epidemic faded away. Subsequently, methicillin
was followed by more easily administered variants such
as cloxacillin and flucloxacillin. 
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Terrifying infectious diseases such as
rheumatic fever, syphilis, pneumonia
and tuberculosis became treatable
and their disappearance seemed 
predestined.
«
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The life of the actress Elizabeth
Taylor was rescued after she was
treated for staph pneumonia during
the shooting of the film Cleopatra
«
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Parke Davis extracted what came 
to be known as chloramphenicol 
from rotten vegetable remains 
sent from Venezuela
«
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resistant to an enzyme called penicillinase. 
This is produced by most Staphylococcus aureus
and some other bacteria, and it destroys penicillin.
But just as bacteria find new strategies to put
antibiotics out of action, chemists have tricks 
too. By adding large bulky groups to the penicillin
structure, it was possible to stop penicillinase from
disabling the drug. As a result of this strategy, the
semi-synthetic agent methicillin soon became the
main clinical weapon against staphylococci that
acquired resistance to penicillin. 
Vancomycin, a glycopeptide, was first purified in 1956,
but understanding how it works took three decades’
work. Gaining insight into its mechanisms was crucial
because vancomycin has become the ‘antibiotic of 
last resort’ for the treatment of methicillin-resistant
Staphylococcus aureus (MRSA). Chemically speaking,
vancomycin is unusual: it is not related to other
antimicrobials in use today. Although it also works 
by disrupting the bacterial cell wall, it latches onto 
the peptide strands directly, preventing them from
growing into a polymer chain. Unfortunately, strains 
of vancomycin-resistant bacteria have been reported 
(see below).
Bacteria bite back
Shortly after penicillin came into widespread 
use, a strain of resistant S. aureus emerged. But
pharmaceutical companies developed a string of other
drugs, including new versions of penicillin, that could
control these strains. Clinicians were confident that,
should a bacterium develop resistance to a particular
antibiotic, throwing another drug at it would work.
So how do bacteria pull off this survival trick? Natural
selection is the key. Bacteria multiply rapidly, going
through many cell divisions a day, and some cells 
may acquire random genetic mutations. If the genetic
change happens to affect the target molecule of an
antibiotic, for example, those bacteria could become
BLOCKING THE TUNNEL
Estonian biochemist Tanel Tenson is investigating
how macrolides stop bacteria producing proteins.
The 1970s were the halcyon days of antibiotics:
bacteria were vanquished and infection rates were
slashed. No one seemed to mind that how the drugs
worked remained a mystery. Today, as antibiotic-
resistant bacteria have become a worldwide problem, 
Dr Tenson agrees that figuring out how antibiotics work 
is a priority. “This is the time to re-investigate several
issues that were left open during the 1970s,” he says.
His research has examined how antibiotics target
ribosomes, the protein-making factories in cells. 
“The ribosome is especially fascinating – it is the
target for many important antibiotics,” says Dr Tenson.
If antibiotics bind to ribosomes and hinder their action,
protein manufacture stops and the bacterium dies.
Dr Tenson focused initially on erythromycin and its
relatives, a widely used class of antibiotics known 
as macrolides. Normally, in a bacterium, the growing
protein emerges from the ribosome through a tunnel-
like structure. Macrolides interrupt this process by
binding to the tunnel opening. “The peptides cannot
enter the tunnel and the ribosome is inactivated,” 
he explains.
But how does this blockage eventually kill the bacterium?
When the macrolide binds to the ribosome, it stalls
peptide production and the nascent peptide remains
attached to transfer RNA (tRNA), the transporter
molecules of amino acids, without letting go. Since
tRNA is usually recycled in the cell, this leads to 
a tRNA shortage, which is probably what stops the
bacterium growing. “This is new and unexpected,
because it is the missing link,” says Dr Tenson.
Dr Tanel Tenson is at the Institute of Technology, Tartu University,
Estonia, and is a Wellcome Trust Central European Senior
Research Fellow.
DNA
Cell
membrane
Cell wall
Ribosomes
(protein synthesis)
RNA
Folic acid
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ANTIBIOTIC TARGETS IN BACTERIA
Inhibition of...  
Cell wall synthesis
Penicillins
Cephalosporins
Carbapenems
Daptomycin
Glycopeptides
DNA synthesis
Fluoroquinolones
RNA synthesis
Rifampin
Protein synthesis
Macrolides 
Chloramphenicol
Tetracycline
Aminoglycosides 
Oxazolidonones
Folic acid synthesis
Sulfonamides
Trimethoprim
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Antibiotics are the great warriors of modern medicine.
These drugs have helped us to defeat infections that 
have threatened human life throughout history. But
over the last decade, we have been losing ground 
at a dramatic pace. Infections considered curable –
including tuberculosis, meningitis and gonorrhoea –
are back to haunt us, and hospitals are infiltrated by
bacteria that defy antibiotics. To quell the antibiotic
backlash, scientists are striving to understand how
antibiotics work and how bacteria resist their effects.
How antibiotics work
The best antibiotics are ‘magic bullets’ – a concept
proposed by Paul Ehrlich in 1906 – that kill infectious
organisms but do not harm the patient. By definition,
antibiotic means ‘against life’, and most such
compounds are natural products, churned out
by bacteria or fungi as chemical weapons to kill 
off other microbes.
The success of penicillin prompted an intensive
search for similar compounds that could kill bacteria
or stop them growing. Researchers sifted through 
the environment – soil, sea and sewer-infested waters
– and came up trumps. Pharmaceutical companies
also optimised the natural products by removing
some chemical groups and adding others, to come
up with new versions with enhanced benefits and
minimal toxicity.
By targeting important biochemical reactions specific
to bacteria, antibiotics tend to be harmless to people
or animals. Some antimicrobials inhibit cell growth,
giving the host’s immune defences a chance to wipe
out the bacteria that remain. These drugs typically
penetrate the microbe and interfere with the production
of components needed to form new bacterial cells.
For example, tetracycline binds to bacterial ribosomes,
which make proteins, and in doing so hinders 
protein production.
Other drugs, such as the purely synthetic quinolones,
stop DNA replication, and some, such as penicillin,
upset the construction of the cell walls that protect
bacteria from the outside world.
The bacterium’s rigid outer wall is critical to the cell’s
survival – it imparts structure and support. Without 
it, the bacterial cell would explode owing to its own 
inner pressure and die. Because human and other
mammalian cells lack such walls, penicillin and 
other related antibiotics (known as beta-lactams) 
are particularly safe.
The wall is made up mostly of peptidoglycan, a material
that contains both peptides and sugars. To assemble
it, peptide–sugar chains must be cross-linked together
by an enzyme called transpeptidase, and it is the action
of this enzyme that is blocked by penicillin. Penicillin
does not really damage existing bacteria, but when the
bacteria divide to make new cells, a new wall cannot
cross-link properly. The wall becomes weak, like 
an ill-woven fabric, until it ruptures, killing the cell.
Although the fungi-derived cephalosporins are
chemically quite different from the penicillins, they
share the same mechanism of action: stopping
transpeptidase. Cephalosporins are more expensive
than penicillin and tend to be used if a person 
is allergic to penicillin.
There are, however, numerous semi-synthetic
derivatives of penicillin, such as ampicillin (used to treat
urinary tract infections), penicillin V and carbenicillin
(used for Pseudomonas infections). These compounds
consist of the basic penicillin structure but have been
modified in the laboratory to make them more stable,
more effective against different bacteria, or more
How do antibiotics work? How do bacteria become resistant to antibiotics?
If we reduced the amount of antibiotics we use, might resistant bacteria lose
the upper hand? Lisa Melton explores the issues.
DRUGS IN PERIL
Antibiotics and resistance 
Researchers sifted through soil, sea
and sewer-infested waters and came
up trumps. 
«
«
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resistant. When confronted with an antibiotic, the
mutants will have the competitive advantage. Natural
selection will ensure that mutants thrive while the rest
are wiped out. That’s the rub: antibiotics are needed to
cure infections, but the more they are used, the greater
the chance of resistance arising and spreading.
Bacteria employ several devices to stave off antibiotic
attack. Some antibiotics must accumulate inside the
bacteria to be effective, and bacteria have pumps on
the cell membrane to expel the drug before it has a
chance to reach its intracellular targets. If a mutation
allows a bacterial cell to overproduce membrane
pumps, it will eject the drug faster than it can diffuse
in. The drug concentration inside the cell will remain
low, and the bacterium will survive.
Another line of attack used by resistant microorganisms
is to destroy the antibiotic warhead. The classic example
is the bacterial production of a lactamase enzyme that
breaks open a ring structure at the heart of penicillin,
rendering it useless. However, if the bacterial enzyme
is silenced, the antibiotic remains useful. (A new drug
called clavulanic acid does just that: mixed with
amoxicillin, a penicillin derivative, it overcomes antibiotic
resistance.) A third bacterial trick is to camouflage or
change the drug target within the bacterium. Some
resistance genes force the bacterium to alter or replace
molecules that antibiotics normally latch on to. If the
drug can no longer bind to its target, the bacterium 
will escape unscathed.
These are nifty survival mechanisms and bacteria 
are good at passing them on. Bacteria not only inherit
useful mutations from their forerunners, but also can
pick up antibiotic resistance from other cells in the
vicinity. Antibiotic resistance genes are easy to pass 
on as they are usually located not on the chromosomal
DNA but on mobile pieces of DNA such as plasmids.
Gene swapping is rampant: bacteria can easily transfer
plasmids bearing one or multiple resistance genes 
to neighbouring bacteria.
Resistance to a single type of drug is problematic 
for doctors treating infection, but not insurmountable:
other antibiotics are usually available. Yet bacteria can
pick up and collect many resistance genes, eventually
acquiring resistance to multiple antibiotics used
against them. When penicillin-resistant S. aureus
became the dominant strain, methicillin seemed the
answer. But bacteria soon became resistant to this 
as well: MRSA has acquired a gene that produces 
a different version of transpeptidase, one that neither
pencillin nor methicillin can bind to with any great
effect. The bacteria can produce cell walls unhindered,
and the antibiotics are rendered irrelevant.
Even vancomycin is losing its power. Bacteria have
developed or acquired alternative ways to make their
walls, a complicated task that involves a cluster of
mutated genes working together. One resistance
mechanism alters the final amino acid D-alanine in the
peptidoglycan chains that form the wall. The antibiotic
normally needs two D-alanines to latch on to; if it can
no longer do this, the peptide chains are free to link
up tightly again to form the wall. Another mechanism
is to substitute D-alanine for a much larger amino
acid, a tactic that keeps vancomycin from binding.
Vancomycin was in use for 30 years before resistance
first emerged in gut flora. These bacteria, known as
enterococci, are normally harmless unless they invade
other parts of the body. But a chill ran through the
clinical world when, in 1997, scientists discovered that
an MRSA strain had picked up vancomycin-resistance
genes. These resistant bugs bypass vancomycin
interference by thickening the peptidoglycan mesh in
the bacterial cell wall without resorting to cross-linking.
Vancomycin’s meddling makes no difference because
thickness has replaced interweaving. 
Resistance and fitness
If bacteria can gain resistance to antibiotics, can they
lose it too? Resistance does not necessarily come for
free: a bacterial protein may be impervious to antibiotic
attack but less efficient at its job; bacteria hosting
plasmids full of resistance genes may take longer 
to replicate their DNA; and producing pumps to expel
antibiotics from the cell, or extra proteins to thicken up
the cell wall, may drain energy that would otherwise be
used for the fastest growth and reproduction possible.
In the presence of antibiotics, resistant bacteria have 
an undoubted advantage: their susceptible peers are
killed off and slow growth is an acceptable price to pay.
But if the antibiotics were removed from use, might the
resistant strains lose their edge, and be outcompeted
by leaner, faster-growing susceptible strains? A key
issue is ‘fitness’, a measure of how well a bacterial
strain can infect a host, persist and proliferate, and be
transmitted to a new host. Although several resistance
mechanisms have been shown to impair fitness, others
seems to be gratuitous, affecting growth little, if at all. 
Even if a resistance mechanism does cause a bacterial
strain to slow down, it may become fitter if it gains
other mutations – compensating mutations – that
ameliorate the costs of resistance. Or, if the resistance
gene is carried on transferable DNA such as a plasmid,
it may get into a strain that can host it more easily. 
Fit strains with potent resistance mechanisms, such 
as multidrug-resistant Acinetobacter baumannii that
plague intensive care units and the epidemic MRSA
strains that have swept into hospitals, are real
headaches for modern healthcare.
Dr Lisa Melton is a freelance writer based in London, UK.
If the antibiotics were removed from
use, might the resistant strains lose
their edge?
«
«
A chill ran through the clinical world
when, in 1997, scientists discovered
that an MRSA strain had picked up
vancomycin-resistance genes.
«
«PUMP ACTION
Rather than confine obsolete antibiotics to
the scrap heap, scientists are finding ways 
to rejuvenate them. 
At the University of Durham, a team of biochemists 
led by Adrian Walmsley is focusing on the pumps 
that bacteria use to eject antibiotics, siphoning drugs
out of the cell so that they never reach toxic levels.
“Pumps are one of the main mechanisms of
resistance. If we could develop pump-blockers, 
we could use those in a cocktail with the original
drugs,” says Professor Walmsley.
One advantage to targeting pumps is that the blocking
agents could approach the cell from the outside. 
“A major constraint in drug development is that to
attack cytosolic proteins you have to get the drug 
into the cell,” he says. “You need it to be hydrophobic
enough to get into the cell, but also soluble enough 
to get it into tablet form.” As this combination is 
hard to achieve, many antibiotics need to be given
intravenously. Drugs that target membrane pumps
would overcome this constraint.
Another way round the resistance problem would be
to stop bacterial pump production by interfering with
genetic controls. “If you can design a repressor that
blocks those transcription factors on DNA, you’d be
able to switch off expression of the pumps,” Professor
Walmsley points out. To his surprise and delight, the
same compounds that block pumps also bind these
transcriptional regulators – a potential double whammy.
If this approach proves successful, it could resuscitate
a host of valuable antimicrobials that have ceased 
to be useful.
Professor Adrian Walmsley is at the Wolfson Research Institute,
University of Durham, UK, and holds a Wellcome Trust project grant.
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We do not yet know how many species of bacterium
exist – science has identified several thousand species,
and the total number may well run into the millions –
but it is already clear that bacteria are remarkably
diverse. Each species has its own characteristics, and
different strains within just one pathogenic species can
have quite different abilities to cause disease or variable
sensitivity to antibiotics.
With the prevalence of antibiotic-resistant bacteria 
on the up, and their dissemination worldwide, it has
become increasingly important to be able to recognise
and distinguish different strains of the bacteria that
endanger humans. Using sophisticated methods such
as multilocus sequence typing (MLST), the spread of
particularly virulent or resistant strains can be tracked,
their origins traced and the routes of disease
transmission understood.
Profiling bacteria 
MLST has rapidly become the ‘gold standard’ for
characterising strains of important pathogens such
as Streptococcus pneumoniae, Staphylococcus 
aureus and Neisseria meningitidis. In this approach,
the DNA sequences of fragments of seven genes 
are obtained from bacterial isolates, and each of the
different sequences (alleles) at each of the seven
genes is assigned a different number. (The technique
examines metabolic genes, which keep the bacterium
running and, unlike genes involved in colonising 
a human or in resisting antibiotics, tend to evolve
quite slowly.) 
A bacterial isolate can be characterised
unambiguously by a string of numbers – the allelic
profile – that corresponds to the DNA sequences 
at the seven loci. In MLST, isolates with the same
sequences at all seven loci are considered to be 
the same strain and are assigned a ‘sequence type’.
Older methods, such the comparison of patterns 
of DNA fragments in a technique called pulsed-field 
gel electrophoresis, are very good for comparing 
strains within a single laboratory but are not well suited
to comparisons between laboratories. In contrast,
MLST results can be posted on internet databases that
hold a huge amount of information, readily examined 
or added to by researchers worldwide. For any one
species, the database can hold: all the sequences ever
identified for each gene fragment; the known sequence
types and their allelic profiles; the properties of
individual isolates of each sequence type; and basic
information such as country of origin, type of disease
and whether the bacteria were found in a hospital 
or in the community.
International MLST databases of this type have 
been developed for a number of major bacterial
pathogens, and these continue to grow as those
studying the pathogen add data on their isolates 
to the central database.
> continued on page 14
Bacteria are the most numerous and diverse organisms on the planet. 
Brian Spratt explores how the latest techniques are tracking strains resistant
to antibiotics, and shedding light on their origins and spread.
KNOW YOUR ENEMY
Tracking resistant strains of bacteria
“I was due to have an operation at a leading London
hospital. Before I went in, I got a letter from the hospital
saying it was high up in the anti-MRSA league tables. 
I thought: ‘Oh good, that’s one thing I don’t need 
to worry about’.
I’d had an operation four years previously, and on that
occasion, they swabbed me in hospital on my first day
to check I wasn’t bringing any infection in. So I was
surprised that the procedure wasn’t repeated this time
round. They talked to me about the operation, but
didn’t take any swabs.
After the second operation [there were two stages], 
I was suddenly moved to an isolated cubicle in the
High Dependency Unit (HDU), where full isolation
procedures were followed (staff and visitors had 
to wear sterilised gloves and gowns in the cubicle,
and they had to wash their hands in alcohol gel before
coming in). Here, they told me my swab had shown
that I had MRSA but said I had nothing to worry
about because it was isolated in the bladder, 
and they had new antibiotics to treat it there.
At this stage I became very ill. An infection in my chest
spread to my lungs and I needed oxygen, a chest drain
and a tracheotomy to help me breathe. I was also put
on a ventilator for a week. There were several attempts
to take me off but I became agitated, which affected
my breathing, so I had to go back on. I was delirious
during my time in HDU – 33 days in all – and remember
very little of it. It was like a dream.
When I improved, I was taken from HDU to another
isolation ward. When I asked why I wasn’t going back
to the open ward, the nurse hesitated slightly, then 
said I would find it easier to rest in a single cubicle.
Again in this ward, they followed isolation procedures.
The hygiene was good, but they talked about the
MRSA very casually. They said it comes and goes,
we’ve all probably got it, and that I didn’t need 
to worry about it because I wasn’t symptomatic.
Once I could speak and think more clearly, I asked 
a doctor if the MRSA had got into my lungs. He looked
thrown, then said he thought he remembered traces
in the pleural fluid but he could be wrong. Most of the
nurses didn’t know. Eventually I found one who
confirmed I had had MRSA in my lungs. 
All in all I was in hospital for nearly ten weeks –
although my operations and recovery period should
only have taken three. When I left they gave me 
a letter for the district nurse. It said I’d had MRSA
(‘MRSA’ was highlighted in big red letters) – not just 
in the pleural fluids, but in the nose as well. They hadn’t
said that in hospital.
Overall, although care and prevention was excellent,
communication was poor. I have no knowledge of 
the course of the MRSA, how or when I got it, where
or when the tests were taken, or when new negative 
or positive results came in. No one was ever open 
or specific about it; it wasn’t straightforward. Yet 
they were always very clear and precise about 
my operations.”
A patient’s experience of MRSA
When Alison went to a leading London hospital for an operation, 
she expected to be home in three weeks. But after contracting 
MRSA, it was a different story.
MRSA MYSTERY
I was delirious during my time in 
the High Dependency Unit – 33 days
in all – and remember very little of it. 
It was like a dream.
«
«
‘MRSA’ was highlighted in big 
red letters.
«
«
Using multilocus sequence typing,
the spread of particularly virulent 
or resistant strains can be tracked,
their origins traced and the routes 
of disease transmission understood.
«
«
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MLST has been extremely useful for clarifying how
different countries’ antibiotic-resistant strains relate 
to one another and for establishing a common
nomenclature. Using a central database at
www.mlst.net, a microbiologist can determine whether
a major antibiotic-resistant strain in their country is new
(perhaps having emerged there), or has already been
reported from other countries (suggesting that it has
been imported). Important new strains of antibiotic-
resistant Streptococcus pneumoniae are now defined
by MLST, and the previously chaotic naming of strains
of methicillin-resistant S. aureus (MRSA) has been
rationalised using MLST and the molecular features 
of the genes that encode methicillin resistance.
Not all bacteria are amenable to MLST, having too 
little sequence variation in their metabolic genes for
the technique to discriminate between strains. One
such example is Neisseria gonorrhoeae, and so a
technique termed NG-MAST, which examines the
variation in two rapidly evolving genes, has been 
used to understand the importation and spread 
of gonorrhoea. In the last few years, the prevalence 
of N. gonorrhoeae resistant to ciprofloxacin, the
standard treatment, has increased so much so that
this drug is no longer considered to be the antibiotic 
of choice for uncomplicated gonorrhoea. 
The resistant strains emerged in the Far East, and 
NG-MAST has shown that those in the UK were at 
first unique strains, associated with male heterosexuals
with a history of sex tourism. Now, however, large 
clusters of people share the same strain. People 
within these large clusters report high rates of partner
exchange, suggesting that the increased prevalence 
of resistance is largely due to the introduction and 
endemic spread of ciprofloxacin-resistant strains 
within such high-risk groups.
The origins of resistance
A close study of bacterial DNA can also shed light 
on the origins of resistant strains. New strains 
emerge and then start to accumulate genetic 
variation, resulting in the presence within a bacterial
population of many sets of related strains (sometimes
called clonal complexes), each typically including the
ancestral genotype and a diverse set of minor variants.
Computer software that models such family trees and
maps the presence of resistance genes shows that
while the resistant strains of a pathogen often spread
and gradually diversify, the resistant genes sometimes
move into new strains. Both of these mechanisms 
are evident in the emergence of penicillin-resistant 
S. pneumoniae and MRSA. Furthermore, individual
strains may acquire resistance repeatedly, and this 
is also seen in MRSA: the most prevalent antibiotic-
susceptible S. aureus strains in hospitals have become
methicillin-resistant repeatedly, acquiring different 
forms of the methicillin resistance genes.
Resistance tends to emerge in those strains that are
most exposed to antibiotics. In community-acquired
S. pneumoniae, penicillin resistance has emerged
largely in those strains that tend to colonise the
nasopharynx of children, while in S. aureus it is the
prevalent antibiotic-susceptible strains within hospitals
that have gained resistance to methicillin. These
hospital strains may already be particularly well
adapted to colonisation and transmission among
patients and healthcare workers in hospitals; acquiring
resistance gives them a further edge, and the new
strains come to dominate where antibiotics are widely
used. The new strains are likely to be the ones in
which resistance to further classes of antibiotic will
appear, leading to the build-up of successful multi-
resistant strains in hospitals. 
This appears to have occurred in S. aureus, where
methicillin resistance (and subsequently multiple
antibiotic resistance) has arisen within the most
widespread susceptible strains, and decreased
susceptibility to vancomycin has also recently
appeared in these successful MRSA strains.
It was once the view that acquisition of resistance
resulted in bacteria that were somewhat crippled. 
If antibiotic usage were reduced, the theory went,
the resistant strains would be outcompeted by fitter
antibiotic-susceptible strains and thus eliminated. 
It is now realised that natural selection reduces 
or eliminates any ‘cost of resistance’ and it appears
that well-established antibiotic-resistant strains have
only slight reductions in fitness. The most problematic
strains have also gained resistance to many of the
available classes of antibiotic; limiting the use of only
one antibiotic class is unlikely to have any significant
impact on the prevalence of such strains. 
The very high rates of MRSA and some other
pathogens in hospitals could arguably be due to very
high levels of selection for resistant strains, resulting
from frequent antibiotic usage. However, the increasing
recovery of MRSA strains in the community – or the
rapid international spread and high prevalence in many
countries of multi-resistant S. pneumoniae among
children – makes it hard to argue that antibiotic-
resistant strains are substantially disadvantaged.
Reversing the high prevalence of antibiotic strains 
in hospitals or the community is unlikely to be easy.
Professor Brian G Spratt is at the Department of Infectious Disease
Epidemiology, St Mary’s Hospital, Imperial College London, UK, 
and is a Wellcome Trust Principal Research Fellow.
Multi Locus Sequence Typing homepage: www.mlst.net
Natural selection reduces or 
eliminates any ‘cost of resistance’
«
«
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The most prevalent antibiotic-
susceptible S. aureus strains in 
hospitals have become methicillin-
resistant repeatedly. 
«
«
Other E. coli strains are the major causes of urinary
tract infections, and most cases of E. coli blood
poisoning reflect overspill from these infections. Here
there are growing resistance problems. More than 
half the isolates are resistant to ampicillin and about 
a fifth are resistant to trimethoprim. Worse, there 
is fast-emerging resistance to the cephalosporins 
and quinolones such as ciprofloxacin. Until recently,
these were very good treatments but now we’re 
being pushed towards using carbapenems for severe
infections with E. coli. These are powerful, injectible
antibiotics that we’ve previously tended to keep 
in reserve.
Which bacteria are cause for most concern?
We are in most trouble with some of the Gram-
negative pathogens that mostly affect patients in
intensive care, especially Acinetobacter baumannii.
Over the years, it has become progressively more
resistant to all antibiotics and there are now strains
circulating that have resistance to carbapenems,
which were the last good line of defence. Some
intensive care units in London are now having to use
polymyxin, a rather toxic old antibiotic that had largely
been abandoned for systematic use. And there is little
in the way of new antibiotics becoming available that
are active against Acinetobacter. There is one new
tetracycline analogue but, beyond that, nothing. 
So, treatment options are narrowing against Gram-
negative bacteria. These include both E. coli, a very
common pathogen, and Acinetobacter, which is less
frequent, but is important in intensive care medicine.
And against some of these less common intensive
care pathogens, we’re being forced to use some not
very good, and rather unpleasant old antibiotics.
Dr David Livermore is Director of the Health Protection Agency’s
Antibiotic Resistance Monitoring and Reference Laboratory,
Colindale, London, UK.
ANTIBIOTIC RESISTANCE IN THE UK
MRSA in England and Wales
MRSA levels, shown here as proportions of bloodstream
infections (bacteraemias), rose dramatically in the mid-to-late
1990s, but have plateaued in the last few years.
Hospitals affected by EMRSA-3, -15 and -16
The increase in MRSA in UK hosptials is largely attributable
to two strains: epidemic MRSA-15 and -16. These strains
are easily transmissible and well adapted to hospitals.
Other strains, such as EMRSA-3, have stayed at relatively
constant levels.
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Ciprofloxacin resistance in E. coli
E. coli infections of the blood and cerebrospinal fluid have
become increasingly resistant to the quinolone ciprofloxacin.
Courtesy of Dr David Livermore, HPA.
16
What’s the role of your laboratory?
We’re the UK’s national reference laboratory. 
When hospitals find bacteria with unusual or 
unknown resistances, they can send them to us for 
the resistance to be confirmed, for treatment advice,
and for the public health importance to be gauged.
We also do research on the mechanisms of resistance,
and work together with epidemiologist colleagues 
on the surveillance of antibiotic resistance. 
Reports of resistance to vancomycin – the
‘drug of last resort’ in methicillin-resistant
Staphylococcus aureus (MRSA) – imply that
MRSA infections will soon be untreatable. 
Is this the case? 
MRSA is essentially an infection-control problem. 
In the UK, two ‘epidemic’ MRSA strains, EMRSA-15
and -16, have become dominant and have spread
widely. They are tenacious, but don’t have a huge
spread of resistance to antibiotics. Contrary to what is
often said, we do still have several antibiotics, not just
vancomycin, that are active against MRSA, particularly
against these two strains. 
There have been a few cases of vancomycin resistance
or intermediate resistance in MRSA, but there are half 
a dozen or so new antibiotics coming along that are
active against MRSA. It remains to be proved, though,
whether these are better than vancomycin.
Is resistance to vancomycin common 
in other bacteria?
Resistance to vancomycin is much more prevalent 
in the enterococci [the gut-dwelling Enterococcus
faecium and E. faecalis, which are also opportunistic
pathogens] than in staphylococci, although the
statistics are a little complex...E. faecalis causes 
90 per cent of enterococcal infections, but its rate 
of vancomycin resistance is only 2–3 per cent. 
For E. faecium, the rate of vancomycin resistance 
is 20–25 per cent but it only accounts for only 
10 per cent of enterococcal infections, mostly in
specialist units such as renal units, transplant units
and haematology units. It’s not like MRSA, which
causes infections widely in hospitals.
Resistance in Streptococcus pneumoniae
is quite high in some parts of the world. 
How does the UK compare? 
In the UK, we don’t have a big resistance problem 
in S. pneumoniae – 3–5 per cent have resistance 
to penicillin, and this is usually low-level resistance
which can be overcome by increased doses, except
in meningitis. Rather more, 12–15 per cent, are
resistant to macrolides. So, as long as the patient 
is not allergic, you usually can give them a high dose
of penicillin. If they are penicillin-allergic, then the rate
of macrolide resistance is perhaps pushing us to use
alternatives, such as fluoroquinolones. If you go to
the USA, southern Europe or South-east Asia, there
are much bigger problems with penicillin resistance 
in pneumococci, probably as a result of more
community prescribing and selection pressure. 
Do bacteria that cause food poisoning show
significant resistance to antibiotics? 
By and large you wouldn’t treat a Salmonella gastro-
intestinal infection with antibiotics: you just let it burn
itself out. But resistance has been going up, both 
to quinolones and cephalosporins, so when you do
have to treat someone – for example, a neonate with 
a salmonella meningitis or someone with typhoid fever
– it is getting harder. Campylobacter shows increasing
fluoroquinolone resistance, but alternative drugs are
macrolides, where there still isn’t much resistance.
Escherichia coli is more complex, because different
strains cause different problems. Many strains live
harmlessly in the gut, but some – such as E. coli 0157
– can cause dangerous gastrointestinal disease. By
and large, you wouldn’t treat infections due to these
strains with antibiotics, but nor are they very resistant.
Dr David Livermore, Director of the Antibiotic Resistance Monitoring 
and Reference Laboratory, sees bacteria from hospitals across the UK. 
And not just any bacteria: these are the strains most resistant to antibiotics.
THE RISE OF RESISTANCE
Resistance in the UK
WellcomeFocus 2005 The rise of resistance
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Every week, hospitals treat thousands of people – of 
all ages and with diverse illnesses and injuries. A huge
quantity of antibiotics is prescribed to treat or prevent
bacterial infections, and it is in hospitals that the intense
relationship between antibiotic use and the development
of antibiotic resistance in bacteria is most evident.
Development of resistance is only part of the problem,
however. Resistant strains of bacteria have spread in
and between hospitals, partly under the pressure of
antibiotic use but sometimes because infection control
has been less effective than it could have been.
Unfortunately, for a variety of reasons, methicillin-
resistant Staphylococcus aureus (MRSA) is now
endemic in many UK hospitals and other healthcare
settings such as care homes. Large ‘specialist’
hospitals face particular problems as their patients
tend to be sicker and more prone to being colonised 
or infected by typical hospital pathogens. The spread 
of resistant bacteria such as MRSA is preventable, 
as countries such as Sweden, Denmark and The
Netherlands have shown, with their successful use 
of a tactic known as ‘search and destroy’. In the 
UK, however, infrastructure and bed occupancy 
rates have hampered efforts: many UK hospitals 
do not have isolation facilities, and bed occupancy 
has risen to such high levels (more than 90 per cent 
of beds are occupied by patients at any one time) 
that it is extremely difficult to separate patients from 
one another and so prevent the spread of antibiotic-
resistant bacteria. Thus, ‘search and destroy’ control
measures have been undermined by the way in 
which patients are typically managed in the UK.
While almost all infections with antibiotic-resistant
bacteria can still be treated, there is evidence that
outcomes are worse in some cases. For example,
death rates in people with bloodstream infections 
of MRSA are twice those seen in people infected 
with susceptible S. aureus strains. 
Infection control 
Isolating patients and scrupulous hand hygiene – such
as with alcohol-based hand rubs – appear to help slow
the spread of bacteria. Indeed, the plateauing of UK
MRSA rates in the last three or so years may be owing
to improvements in these areas (although the bacteria
themselves may have reached a threshold). But much
of infection control practice is based on empiricism –
experience rather than data holds sway. Effective ways
of preventing cross-infection and the spread of
antibiotic-resistant pathogens still need to be defined
and/or refined. Crucially, these approaches may need
to differ depending on whether a particular antibiotic-
resistant pathogen has already become established
(i.e. is endemic) or whether it is rare. A good analogy
here is plugging the holes in a leaking dyke: eventually
more than fingers will be needed to sustain the barrier. 
Control measures also need to be practical, given
available resources. For example, new methods 
to detect MRSA earlier, including new tests that cut
detection times from two days to two hours, may 
not actually reduce infection risk unless effective
treatments or preventative approaches (such as the
capacity to segregate patients) can be implemented.
Much has been written about hospital cleanliness 
and the risk of hospital infection, notably the spread 
of MRSA, but the lack of data to substantiate a link
between these is stark.
We also do not know what happens when we stop
using compromised antibiotics. There is evidence 
that some types of resistance will persist, while other
types are reversible (if, for example, the prescribing 
of a specific antibiotic is restricted). But, perhaps
The spread of resistant bacteria in hospitals has become a major public health
and political issue. But Mark Wilcox points out that we do not necessarily
know the most effective ways to control this spread.
LIFE ON THE WARD
Antibiotic resistance in hospitals
“Alexander Fleming warned us that the more we
expose people to penicillin, the greater the risk of
antibiotic resistance. It is less of a problem in the 
UK than elsewhere in the world, because we can 
only get antibiotics here on prescription: people 
cannot just walk into a pharmacy and buy them. 
And in UK hospitals, we have microbiologists to 
guide us in prescribing the most appropriate 
antibiotics for particular cases.
But patients are still being given unnecessary antibiotics.
They may come into hospital with a chest infection
exacerbating an underlying condition, such as chronic
obstructive pulmonary disease, and get put on
pneumonia antibiotics – which they do not need
because they have not got pneumonia. Doctors have 
a real responsibility to tailor antibiotic use as narrowly
as possible to a particular patient situation. If we kill
only the organism that is causing the disease,
resistance is less likely to develop.
Unfortunately, this is easier said than done. We cannot
always culture and target the initial infecting organism,
so we have to give broad-spectrum antibiotics. As 
an example: in 30 per cent of cases of community-
acquired pneumonia, we don’t know the cause.
Legionella wasn’t isolated until 1976, before which
people died of ‘unknown pneumonia’.
Although it must be frightening to have an organism
that is resistant to antibiotics, methicillin-resistant
Staphylococcus aureus (MRSA) is not the greatest
worry we face. People do die of it, but it is not a 
pandemic wiping people out in hospitals. MRSA 
is not a superbug, it is a weak pathogen, which 
gets selected out of people’s bodies by far more 
pathogenic organisms. The problem is complicated 
by the fact that patients get infected with MRSA 
when they are already very ill. So a person who has 
got septicaemia can then get MRSA – but it is the
septicaemia that kills. So the question is: did they 
die of MRSA or just with it?
I am more worried about tuberculosis (TB) than MRSA.
TB is still a killer worldwide, with a higher resistance
when found in people from India. This is partly because
there are more TB bacteria in India, hence a greater
chance of catching a resistant one, and partly because
people have to pay for TB treatment and may opt for
cheaper generic drugs, which may be manufactured 
to less rigorous standards than in the UK.
In the UK, we offer four drugs to make sure we 
cover all the TB bacteria for the first two months. 
An individual is unlikely to have resistance to more
than one – so there will be three effective drugs.
Elsewhere in the world, treatment is interrupted as
patients run out of money, war breaks out or resistance
emerges. This raises the ethical question: should 
a doctor start someone on TB treatment if there is 
no guarantee they will finish? If the patient develops
resistance, this makes it worse for them and for
everyone else.”
Dr Graeme Wilson is at Newham Hospital, London, UK.
Graeme Wilson, a consultant respiratory physician, argues that MRSA is weak
compared with other disease-causing agents, and not our greatest worry.
“MRSA IS NOT A SUPERBUG” 
A doctor’s view of MRSA
Doctors have a real responsibility 
to tailor antibiotic use as narrowly
as possible to a particular patient 
«
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The spread of resistant bacteria such
as MRSA is preventable, as countries
such as Sweden, Denmark and The
Netherlands have shown.
«
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surprisingly, there is little robust information on how
best to optimise and regulate antibiotic prescribing 
in hospitals. Many data have been collected about 
the extent of antibiotic resistance, but rarely is it also
determined how commonly antimicrobials are used.
So while we know that antibiotic prescribing by GPs
has declined recently, comparable information on
antibiotic prescribing in hospitals – at the national level
– is not freely available. We also need to know more
about the long-term effectiveness of restricting
antibiotic prescribing, especially where one drug 
is substituted for another, or where antibiotics are
rotated in a hospital or unit (to reduce the time that
any one antibiotic has to induce resistance). While
antibiotic rotation is attractive in theory, it has yet 
to be proved both sustainable and efficacious 
at reducing levels of resistance.  
More uncertainty
We need to know a lot more about the genes that
allow bacteria to resist antibiotics. For example, there
is uncertainty about the potential for genes to jump
from bacteria carried often harmlessly by humans 
or animals (such as the normal flora in the gut) 
to pathogenic bacteria. An important area for progress
is predicting more rapidly when infections are likely 
to respond to which antibiotics. This need extends
beyond knowing whether or not a bacterium has a
certain resistance gene; we also need to know about
what makes it so effective (its virulence determinants)
and accessory genes that may control its response 
to antibiotics. For example, there is increasing
evidence that bacterial regulator genes may affect 
the likelihood of vancomycin therapy succeeding
against MRSA infection.
It is important to recognise that antibiotic resistance
does not respect boundaries between hospitals and
the community; the interplay between these pools 
of resistance genes is not well understood. Recently,
virulent strains of so-called ‘community-associated’
MRSA (to distinguish them from healthcare-associated
strains) have emerged. Such strains have different
resistance genes and have spread in a number of
groups – such as children, sports teams and prison
inmates – previously not considered to be at increased
risk of MRSA infection.
Another recently reported phenomenon is the
emergence of Gram-negative bacteria that can produce
enzymes (beta-lactamases) rendering commonly used
antibiotics – penicillins and cephalosporins – ineffective.
For example, resistance to third-generation (extended-
spectrum) cephalosporins in E. coli – a common cause
of urinary tract infections and sometimes serious
invasive infection such as septicaemia – has remained
below 10 per cent in most European countries.
However, there are sporadic reports of more prevalent
resistance emerging in some UK hospital and
community settings and in some eastern European
countries. There has also been a consistent and
marked rise in fluoroquinolone-resistant Gram-negative
bacteria and, worryingly, clinicians are now faced with
the emergence of Gram-negative bacteria resistant 
to all approved antibiotics (such as Acinetobacter
species; see page 17).
As the length of hospital stays decreases, and as 
in general community and secondary care become
more closely interwoven, our surveillance for and
understanding of the epidemiology of antibiotic
resistance emergence will have to become a lot 
more sophisticated.
Concluding thoughts
We must not overplay the issue of antimicrobial
resistance, and patients can be reassured that the
vast majority of infections remain treatable. However,
we must never assume that we have finally beaten 
the microbes, no matter what new drug is discovered;
rather, we must try to remain one step ahead.
Antibiotic prescribing must be used judiciously.
Vaccination against infectious diseases – which has
transformed medicine – has the potential to make
significant inroads into the control of healthcare-
associated pathogens. For example, a vaccine against
S. aureus has given promising results in clinical trials. 
Last but not least, hospitals need to prioritise good
infection-control practice – resources spent on waiting
lists targets need to be redirected or preferably
increased. Hospitals of the future need a greater
supply of single-room accommodation to help contain
the spread of antimicrobial resistance.
Mark Wilcox is Professor of Medical Microbiology, Clinical Director
of Microbiology, and Director of Infection Prevention and Control 
at Leeds Teaching Hospitals and the University of Leeds, UK.
Antibiotic resistance does not
respect boundaries between 
hospitals and the community
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Using MLST, Dr Enright has found that community-
acquired strains are very different from hospital
strains: “There was an idea that they were feral
hospital strains, but this is not the case.” Instead,
some community isolates turn out to be descended
from a penicillin-resistant strain of S. aureus that
appeared in the 1950s (see page 6). The type 80/81
strain was notable in its day for being unusually
transmissible and virulent, and was probably the most
frequent cause of severe staphylococcal disease 
in the mid-to-late 1950s. This strain was supposed 
to have been vanquished by methicillin in the 1960s.
Not so, Dr Enright and colleagues have found: 
the strain has persisted and is now re-emerging 
in the community, this time resistant to methicillin. 
If the evolution of MRSA continues apace, the 
concepts of hospital and community MRSA strains
may become blurred. As Dr Enright points out:
“Community strains could become more like the 
hospital strains in terms of antibiotic resistance and
become harder to treat. Or hospital strains could
become more dangerous if they acquire toxin genes,
and could cause serious disease in younger, healthier
people. You might not need catheters to have MRSA
in hospital. These would be worrying developments.” 
Dr Mark Enright is at the Department of Infectious Disease
Epidemiology, Imperial College London, UK, and holds 
a Wellcome Trust project grant.
MRSA: GENOMIC CONFESSIONS
Within the genome sequence of Staphylococcus
aureus are the genes that make it tick, that
enable it to colonise a human and perhaps
cause disease, and that, in some strains, help 
it to resist antibiotics. By Matt Holden.
These genes are not necessarily ‘home-grown’:
with the genomes of several strains complete, it is
becoming clear that S. aureus is adept at acquiring
and transferring mobile pieces of DNA containing
resistance genes. 
The genomes of two S. aureus strains were
completed at the Wellcome Trust Sanger Institute
in 2004. MRSA252 is a hospital-acquired
representative of the epidemic methicillin-resistant
EMRSA-16 clone responsible for half of the MRSA
infections in UK hospitals, while MSSA476 is an
invasive community-acquired methicillin-susceptible
strain (MSSA). 
Approximately 80 per cent of the S. aureus genome
is common to all the strains. Here lie many of the
genes that keep the bacterium running and help it
to colonise or infect humans. The regions that differ
are of variable size, are scattered throughout the
genome and contain genes found in only one, 
or a few, of the strains. These regions often contain
genetic elements that can be transferred between
strains. One such element in MRSA252 – termed
the staphylococcal chromosome cassette – carries
the methicillin resistance gene as well as genes that
confer resistance to erythromycin, spectinomycin,
kanamycin and bleomycin. The chromosome 
of MRSA252 also contains another two mobile
elements carrying a beta-lactamase (an enzyme
that destroys penicillins), and erythromycin and
spectinomycin resistance genes. In fact, all but 
one of the antibiotic resistance genes in MRSA252
are encoded on mobile genetic elements.
The methicillin-sensitive strain MSSA476 is resistant
to fewer antibiotics, but has also gained a selection
of mobile DNA elements. With the exception of
genes in two regions in the genome, all of the genes
in MSSA252 are found in a community-acquired
strain called MW2 (whose genome has also been
sequenced), closely related to MSSA252 but
methicillin-resistant. Since these strains diverged
from a recent common ancestor, it appears that five
horizontal exchange events have occurred. Strikingly,
the two strains have staphylococcal chromosome
cassette elements carrying different antibiotic
resistance genes at the same location on their
chromosomes. In the case of MSSA476, it contains
a novel type of cassette with a gene that confers
fusidic acid resistance. 
This comparison illustrates the important role that
mobile elements have in gene exchange within
lineages, and the potential for rapid emergence 
of new drug-resistant strains of this pathogen.
Dr Matt Holden is at the Wellcome Trust Sanger Institute, UK.
Community strains could become more
like the hospital strains and become
harder to treat. Or hospital strains could
become more dangerous if they acquire 
toxin genes
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At the beginning of the 1990s, UK hospitals started 
to identify two new strains of methicillin-resistant
Staphylococcus aureus (MRSA). Such resistance was
nothing new: the first case had been found in 1961,
just one year after methicillin had been introduced.
But these new strains spread with such astounding
efficiency that, a decade later, most UK hospitals 
have been infiltrated.
“Modern medicine gives these organisms easy entry 
to the body,” says Mark Enright. “More invasive
surgery is being performed, more catheters are being
put into people’s bloodstreams, and an older, sicker,
more vulnerable population is being treated. Someone
comes along having treated a patient with MRSA, their
fingers touch the catheter of a different patient, MRSA
gets into the body and invasive disease results.” 
The two strains, epidemic MRSA-15 and -16, seem 
to be particularly well suited to life in hospitals. They
can live for up to six months on surfaces, are easily
transmitted between people, and cause infections
around wounds as well as life-threatening conditions
such as bloodstream infections, pneumonia and
infection of the heart lining. Today, in UK hospitals,
more than 40 per cent of S. aureus infections are
resistant to methicillin, other penicillin-class antibiotics
and often additional antibiotics. 
Doctors have still had the glycopeptide vancomycin
as backup but, worryingly, resistance to this ‘drug 
of last resort’ has emerged in the last few years.
“Intermediate resistance was identified in Japan 
in 1997, and these isolates have now been found in
every country,” says Dr Enright. “And there have been
three separate isolates of full vancomycin resistance
found in the USA in 2002 and 2004. So resistance 
to the newest antibiotics already exists.”
Tracking MRSA
Using multilocus sequence typing (MLST; see page 13)
to ‘DNA profile’ different strains of S. aureus, Dr Enright
is seeing where they are descended from and how they
fit into families. “Data from more than 1000 isolates of
S. aureus from about 15 different countries are in the
database,” he says. “You can see where a strain has
spread in the world, if it has caused disease in children
or adults, and if it is in hospitals or communities.” 
Using these data, Dr Enright has found that today’s
hospital MRSA strains descend from five original strains
that independently gained methicillin resistance. “MLST
shows the global epidemiology of different strains and
their evolution in the long term,” he says. “We can plot
the relationships between the strains and see how
descendants emerge.” These strains have also spread
worldwide: “Whatever you find in the USA you’ll find 
in the UK, albeit at a low frequency at first. Even when
we tested strains from Cuba – from local hospitals that
aren’t accessed by tourists – we found that hospital
strains are similar to those in other countries.”
Not all cases of MRSA arise in hospitals. Community-
acquired MRSA seems to cause disease in children
and young adults, and is rare in the UK (only about 
100 cases have been identified in the last three years)
but more prevalent in the USA, mainland Europe and
Australia. The strains involved are resistant to fewer
antibiotics than hospital MRSA, but produce a
dangerous toxin (called PVL) that can lead to skin
infections such as large boils or clusters of boils (up 
to 10 cm in diameter in some cases) and deep-seated
abscesses. If the bacteria get into the lungs, which is
fortunately a rare event, a devastating pneumonia that
kills more than 40 per cent of patients can result. 
Why have two strains of methicillin-resistant Staphylococcus aureus (MRSA)
infiltrated UK hospitals? How do they relate to MRSA elsewhere in the world 
and to ‘community-acquired’ strains? Mark Enright is tracking the answers. 
TRACKING THE OPPORTUNIST
Methicillin-resistant Staphylococcus aureus
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Cutting back
Given reports that antibiotic growth promoters 
had created a huge reservoir of resistant bacteria 
in animals, and documented examples of the
transmission of these resistant bacteria from animals
to humans, governments have taken action. Denmark
has been a leading proponent of such moves. In 1995,
it stopped the use of avoparcin as a growth promoter,
and in just three years the prevalence of vancomycin-
resistant enterococci in Danish poultry fell from over 
80 per cent to under 5 per cent. In 2000, the use 
of any antibiotic growth promoters was stopped and,
in 2003, strict regulations were imposed on the use 
of quinolones in animals. Danish vets can now only
prescribe quinolones if they can document that no
other antibiotics would be effective. This has markedly
reduced the use of quinolones in animals and limited
the occurrence of resistance.
Europe-wide measures have also been taken. The use
of avoparcin in animals was banned in 1997, and all
uses of antimicrobials for growth promotion will be
banned from 2006. The impact on farmers may be
smaller than feared: five years after Denmark stopped
the use of antibiotic growth promoters, only minor
negative effects have been seen (some pig herds have
seen diarrhoeal problems in weaned piglets). There has
been a rapid and major decline in the occurrence of
bacterial resistance to these antibiotics in animals and
food, and Danish food animal production has continued
to increase. With modern farming practices, it may well
be that antibiotic growth promoters are simply not as
necessary as they were in the past.
Dr Henrik C Wegener is at the Danish Institute for Food 
and Veterinary Research.
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It is estimated that more than half of all antibiotics
produced worldwide are used in animals. Although
some are for our companion animals, most are used
on food animals: to treat infections that can devastate
herds, to prevent infections or to boost production.
But worries have arisen that, in the long term, human
health could be severely threatened. All of the different
types of antibiotic that are used in animals are also
used in humans, and mounting evidence of resistant
bacteria developing in animals and infecting humans –
or passing their resistance genes onto human-infecting
bacteria – is leading governments to cut back animal
antibiotic use.
Animals and humans
As they are kept in large, high-density groups and
often raised to slaughter weight before they reach
physical maturity, it is not surprising that food animals
can develop and spread infectious diseases easily. 
In response, farmers have used antibiotics liberally 
to keep their stocks healthy. Entire groups of animals
are treated as soon as clinical symptoms appear in
one animal, and many groups of animals are treated
before symptoms appear. But the most controversial
use of antibiotics – and the most common use – is 
in ‘growth promotion’. By some mechanism, as yet
unclear, the addition of low doses of antibiotics to
animal feed can enhance growth rates and increase
feed efficiency. Such antibiotics can be used
throughout an animal’s life.
Any use of antibiotics can lead to the development 
of resistance. In general, high concentrations used 
for a short time, such as when treating sick animals,
are less likely to lead to resistance than low dosages 
for a long time, such as in growth promotion. And
resistance has indeed arisen: before the growth
promoter avoparcin was banned in Denmark in 1995,
80 per cent of Danish broiler chickens had enterococci
resistant to the human antibiotic vancomycin, a close
relative of avoparcin.
But does the use of antibiotics in animals actually
affect human health? While we do not know how
much of the resistance problem seen in humans is
attributable to animal use of antibiotics, clear examples
have been seen with Salmonella and Campylobacter.
These bacteria cause an estimated 200 million
infections, primarily diarrhoea, worldwide each year;
most of these infections originate from animals. 
In recent years, a multi-resistant form of Salmonella
(S. typhimurium DT104) has spread in animals, foods
and, subsequently, in humans. The massive spread 
of this strain around the world has been attributed 
in part to its advantage in environments with frequent
antibiotic use. Studies have indicated that this multi-
resistant strain may cause more severe infections 
in humans.
Another worrying trend has been observed recently.
Salmonella and Campylobacter strains resistant to
quinolones have emerged in animals and spread to
humans. These drugs are used routinely in humans 
for the treatment of acute and severe diarrhoea, but
recent studies have shown that infections with
quinolone-resistant Salmonella and Campylobacter
tend to be more severe and more often fatal compared
with infections with sensitive strains.
Antibiotics keep food animals healthy. But their use is being curtailed 
amid growing evidence that resistant bacteria can spread from animals 
to humans, as Henrik Wegener describes.
THE FOOD CHAIN 
Antibiotic use in animals
All of the different types of antibiotic
that are used in animals are also
used in humans
«
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Urinary tract infections
High degrees of antibiotic usage have often been
linked to increased levels of resistance. This is the case
both internationally (in countries where antibiotics can
be bought over the counter, resistance is thought to 
be higher than elsewhere) and locally (GP practices
with high prescribing rates are said to experience
higher resistance). But such associations do not
measure individual exposure to antibiotics: are the
patients receiving antibiotics the same ones from
whom antibiotic-resistant bacteria are isolated? “A lot
of assumptions are made about antibiotic resistance 
in the scientific literature,” says Professor Stephen
Palmer at the University of Wales. “And often they
aren’t based on good evidence.” 
Professor Palmer wishes to clarify the relationship 
at the individual level by weighing up people’s past
antibiotic use against their personal risk of developing
a resistant infection. “The connection is not well 
documented,” he says. He has been tackling the
problem by investigating the incidence of antibiotic
resistance among patients with urinary tract infections
(UTIs) at ten GP surgeries in south Wales. Initially,
Professor Palmer and his team asked the GPs to
request urine samples of all new cases of UTI, rather
than selecting only the cases that were difficult to treat.
About a thousand new cases of E. coli UTI were
identified and linked to each patient’s antibiotic history
(i.e. which antibiotics were taken and when), and 
to the prescribing patterns of the general practices 
of the patients. Preliminary results showed that of 
the thousand cases investigated, half had infections
with bacteria resistant to at least one antibiotic. “We
want to try to find out what is the difference – what
are the risk factors for antibiotic resistance,” explains
Professor Palmer. “This is important because our 
data suggest that patients with a resistant infection
have poorer outcomes and their normal activities are
disrupted for longer.” 
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Hospital-acquired bacterial infections may dominate the
headlines, but most infections occur in the community.
Indeed, 80 per cent of antibiotic prescribing takes place
in the community – in local practices, daycare centres
and long-term care facilities such as nursing homes
and rehabilitation centres. General practitioners (GPs)
have to tackle a wide range of bacteria, including:
Streptococcus pneumoniae; Streptococcus pyogenes,
which most often causes ‘strep throat’, a mild sore
throat; Neisseria meningitidis, an important cause of
bacterial meningitis; Campylobacter and Salmonella,
which cause bacterial gastroenteritis; and Escherichia
coli, responsible for most urinary tract infections – more
than 80 per cent of cases of acute uncomplicated 
cystitis in young women.
The pneumococcus
Community-acquired infection with Streptococcus
pneumoniae (the ‘pneumococcus’) is the leading 
bacterial cause of human illness and death worldwide.
First identified in 1881 by Sternberg and Pasteur, 
the bacterium causes life-threatening diseases such
as pneumonia, bloodstream infection and meningitis, 
as well as sinusitis and acute earache (otitis media) 
– the most frequent illness for which antibiotics are 
prescribed for children in industrialised countries.
Antimicrobial resistance among S. pneumoniae
was first recognised in 1917, when patients with
pneumococcal infections were treated with ethyl-
hydrocupreine (optochin) and resistance developed 
while the patients were in therapy. Penicillin became
the treatment of choice from the 1940s; however, in
the 1960s, the first intermediately penicillin-resistant
pneumococcus of clinical relevance was isolated in
Australia, and in 1974, the first report of infection due
to a fully penicillin-resistant pneumococcus was
described in the USA.
During the 1980s and 1990s, resistance among 
S. pneumoniae became a problem of global 
significance, affecting many countries. For example, 
in the USA, penicillin resistance rose from less than 
5 per cent in the 1980s to 18 per cent in the early
1990s, and increased to 35 per cent by the end 
of the century. Across Europe, about 5 per cent of 
pneumococcus isolates show resistance to penicillin,
but the rates in specific countries can vary markedly:
Spain, Romania and Israel have resistance rates 
of more than 25 per cent, for example, while in the 
UK, Germany and Sweden, among others, rates are 
5 per cent or below. Resistance to the macrolide 
erythromycin has also been increasing in Europe, 
with a similar geographical pattern.
Vaccines can play a key role in preventing the
emergence and spread of resistance in the community,
by reducing the frequency of infection and consequent
antimicrobial use. Efforts to develop effective
pneumococcal vaccines began as early as 1911, 
fell away when penicillin seemed the answer in the
1940s, and then restarted in the late 1960s. A vaccine
suitable for adults was developed in the 1970s, but
recent efforts have focused on a newer vaccine,
suitable for children, which was licensed in 2000. 
In addition to a dramatic reduction in the incidence 
of invasive pneumococcal disease, it was reported 
in March 2005 that the use of this vaccine in US
children was associated with a reduction in macrolide
resistance in S. pneumoniae, an encouraging result. 
Dr Angela Brueggemann is at the Department of Microbiology 
and Infectious Disease, and the Department of Public Health 
and Primary Care, University of Oxford, UK.
Angela Brueggemann discusses the pneumococcus, while Penny Bailey
reports on research in Wales on the correlation between prescribing patterns
and antibiotic resistance.
BACTERIA AT LARGE
Antibiotic resistance in community 
bacterial infections
Acute earache (otitis media) 
is the most frequent illness for 
which antibiotics are prescribed
for children in industrialised 
countries.
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Anti-tuberculosis drugs are two-edged swords. 
They destroy Mycobacterium tuberculosis but can 
also select for resistant bacteria, against which those
drugs are then ineffective. The first anti-TB drugs –
streptomycin, para-aminosalicylic acid and isoniazid –
were introduced in the 1940s, and although resistance
arose soon after, it was always to one drug alone. 
By the end of the 1960s, rifampin had arrived, and 
its use in combination with other drugs led to a
decline in drug-resistant and drug-susceptible TB 
in developed countries. Funding for and interest 
in TB control programmes also declined and, for 
the following 20 years, no systematic monitoring of
drug resistance was carried out.
The situation changed significantly with the arrival 
of HIV/AIDS in the 1980s. The transmission of TB
increased, including more outbreaks of multidrug-
resistant TB (MDR-TB) – strains resistant to isoniazid
and rifampin. In response, the Global Project on 
Drug Resistance Surveillance was launched in 1994 
to monitor trends in resistance. Its 1997 and 2000
reports showed that drug resistance was present
worldwide and that the prevalence of MDR-TB 
ranged from 0 to 14 per cent of new TB cases 
(median: 1.4 per cent) and 0 to 54 per cent of 
previously treated cases (median: 13 per cent).
The recently published third report has data on 77
sites around the world, collected between 1999 and
2002. Significant increases in the prevalence of 
MDR-TB were seen in Estonia, Lithuania, Tomsk
Oblast (in Russia) and Poland, but there were
significant decreases in Hong Kong, Thailand and the
USA. Most western and central European countries 
see only a few cases of MDR-TB each year but,
alarmingly, it was estimated that two provinces in
China (Henan and Hubei) see more than 1000 cases
each year, and Kazakhstan and South Africa more
than 3000 each.
Acquired and primary resistance
Unlike many other bacteria, M. tuberculosis strains
cannot gain resistance by the transfer of mobile 
pieces of DNA containing ‘resistance genes’. Instead,
resistance arises when spontaneous mutations in the
genome cause changes in proteins that are either
directly targeted by the drug, or that control its
accumulation or activation in the cell. Such mutations
are rare, and as the genes involved in resistance to
various drugs are in different parts of the genome, the
risk of a double spontaneous mutation is extremely 
low. Using combinations of drugs (as in the WHO-
recommended directly observed therapy short-course
programme) should therefore preclude the selection
of resistant strains. MDR-TB develops when drugs 
are used individually or as part of inappropriate
combinations. This results in selection of resistant
bacteria within the individual (‘acquired resistance’)
who can then spread the resistant strain to other
people, who will develop MDR-TB as a result of
‘primary resistance’.
Debates have raged over the relative contribution 
of acquired and primary resistance to the burden 
of drug-resistant TB in different communities. The
controversy focuses on whether MDR-TB strains 
can be transmitted between people or whether the
mutations that confer drug resistance also impair
bacterial survival or reproduction. A series of studies
over the last decade, looking at MDR-TB in hospitals,
among healthcare workers, in prisons and in
communities, has provided evidence that MDR-TB 
can be transmitted and has shown that these
dangerous bacteria are expensive to combat 
and constitute a major public health issue.
Multidrug-resistant tuberculosis
TACKLING THE WHITE PLAGUE
Tommie Victor and Douglas Young discuss how molecular approaches 
are increasing our knowledge of drug-resistant tuberculosis (TB).
With the arrival of HIV/AIDS in 
the 1980s, the transmission of TB
increased, including more outbreaks
of multidrug-resistant TB.
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Half of those patients with a resistant UTI (around 25
per cent of the total) had had antibiotic treatments for 
a UTI in the past. Twenty per cent had had antibiotics
for an upper respiratory tract infection, and 6 per cent
for a skin infection. The strongest associations between
previous prescription and resistance identified so far are
for amoxicillin and trimethoprim, resistance being more
likely if the doses were higher and the prescriptions
more recent.
The next step is to find a causal pathway: why one
person gets a resistant UTI while another does not.
Do antibiotics given for respiratory infections (which
are mostly viral) produce resistance in the bacteria
that normally colonise that intestine, leading to a
resistant UTI, for example? Or are people picking up
resistance from someone else in their household?  
The team also aims to work with GPs in evidence-
based prescribing. “At present a lot of prescribing is
done at the theoretical level: by the time the microbial
test results come through, people with negative
results have already received antibiotics,” says
Professor Palmer. Worryingly, in a supplementary
study of patients who sent in a urine sample, the team
found that although 69 per cent of patients had been
given antibiotics for their UTI, 45 per cent did not have
bacteria in their urine. “This may be an untackled area
of unnecessary prescribing,” says Professor Palmer.
Improving prescribing and use
Worries about rising levels of resistance to antibiotics 
in bacteria have focused on whether all prescriptions
are necessary. Patients with an infection – particularly
upper respiratory infections – often expect antibiotics,
and can pressurise doctors to prescribe these even 
if they are unlikely to be effective. The pressures on
both patient and doctor are quite understandable: an
anxious parent, a sick child, and a doctor who may not
be sure at the time whether the infection is caused by 
a virus or a bacterium. In the UK, antibiotic prescribing
by GPs increased in the 1980s, peaked in 1995 and
then fell by over a quarter between 1995 and 2000
(mostly owing to reduced antibiotic prescribing for
acute respiratory illnesses).
One solution would be to help doctors when making
their initial diagnosis. At present, bacteria samples from
a patient have to be sent to a laboratory for testing –
and the results may take several days to return. Quick,
accurate tests that could identify patients with bacterial
infections requiring an antibiotic would make a huge
difference: if the test turned out to be negative, they
would not be given unnecessary antibiotics and risk
developing resistance. Some bacterial illnesses may not
require antibiotics at all. For example, conjunctivitis
affects one in eight school children every year, and in a
recent study in Oxford found that chloramphenicol, the
standard treatment, had little benefit: most children will
get better by themselves. 
Improving GPs’ awareness of a local link between rates
of antibiotic resistance in their patients and their own
prescribing decisions may also change prescribing
patterns and reduce the emergence of resistance. 
But equally important are measures to educate patients
in how to use antibiotics correctly. People often fail to
finish the full course of treatment – as soon as they feel
better, they stop and the leftovers sit in the medicine
cabinet. The incorrect dosing can fail to eliminate the
bacteria completely from the system and will encourage
growth of the resistant strains. 
Professor Stephen Palmer is at the Department of Epidemiology,
Statistics and Public Health, Cardiff University, Wales College of
Medicine, and is an honorary consultant in the UK’s Health
Protection Agency.
Do antibiotics given for respiratory
infections (which are mostly viral)
produce resistance in the bacteria
that normally colonise that intestine,
leading to a resistant UTI?
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The most extensive MDR-TB outbreak reported 
to date occurred in New York, where there were 267
cases of infection by Beijing (or ‘strain W’) strains of M.
tuberculosis. Since then, drug-resistant and susceptible
Beijing strains have been found throughout the world:
for example, a recent study has shown that they
contribute, along with other strains, to the drug-
resistant epidemic in the Western Cape of South Africa.
MDR-TB was first identified in the Western Cape area
in 1985; within nine years it accounted for 2 per cent 
of the TB isolated in the region, and South Africa is now
listed by the WHO as one of the high-burden countries
for drug-resistant TB. Many other MDR-TB strains exist:
smaller outbreaks involving such strains have arisen
recently in the Czech Republic, Portugal and Norway.
Breaking the cycle
How can we stop the transmission of drug-resistant
TB? Rapid diagnosis and new drugs would make a
huge difference, and here our understanding of the
genetics of M. tuberculosis is beginning to bear fruit.
At present, both of these possibilities are problematic.
Once a sputum sample has been taken from 
someone suspected of having TB, it takes three to 
six weeks to grow the bacteria and confirm that they
are indeed M. tuberculosis, and another two to 
three weeks to determine which drugs the strain is 
susceptible to. Such delays leave a critical window 
for MDR-TB transmission. The tests are also costly,
and there are considerable problems with 
standardisation of tests and with stability of the 
drugs in different test media.
New, fast molecular tests are currently being evaluated.
These have been designed to examine the bacteria’s
DNA directly from sputum samples within seven days, 
looking for the specific mutations found in resistant
strains. Future tests may well use DNA chips that look
for multiple mutations at once, such as mutations in the
rpoB gene, which can serve as a marker for MDR-TB,
and mutations in the genes involved in resistance to
isoniazid. Although these techniques have the potential
to be automated and re-used, they are expensive; only
if they become cheap and robust are they likely to 
be used in resource-poor countries, where most 
drug-resistant cases occur.
Equally important is the development of new drugs 
for treatment of MDR-TB. Currently available ‘second-
line’ drugs are more expensive and less effective than
rifampin and isoniazid, and require more intensive 
clinical management. The hope is that the sequence
of the M. tuberculosis genome, and advances in our
understanding of the function of its genes, will provide
a wealth of opportunities for target identification and
drug discovery. This is of course a longer-term 
challenge. But MDR-TB is a manufactured problem
and, with astute application of resources and 
expertise, a manufactured solution is within reach.
Tommie Victor (Medical Biochemistry, School of Health Sciences,
University of Stellenbosch, South Africa) and Douglas Young
(Centre for Molecular Microbiology and Infection, Department 
of Infectious Diseases and Microbiology, Imperial College London,
UK) are supported by a Wellcome Trust Collaborative Research
Initiative Grant to develop rapid tests for MDR-TB in South Africa.
COMBATING TUBERCULOSIS
Henry Nicholls reports on a project that is
tackling drug-resistant tuberculosis in Uganda.
In the late 1990s, scientists working in Uganda
began to notice that some patients receiving
treatment for tuberculosis (TB) were not
responding to conventional drugs. 
A pilot study subsequently revealed an alarming
statistic: in nearly a quarter of patients tested, 
the bacterium that causes TB had developed
resistance to more than one of the drugs that
would normally treat the disease.
With backing from the Wellcome Trust and 
the Burroughs Wellcome Fund, project leader
Jerrold Ellner and his colleagues at the University
of Medicine and Dentistry of New Jersey have
teamed up with researchers at the London School
of Hygiene and Tropical Medicine and scientists in
Uganda. Their first mission has been to verify the
extent of the problem. So far, they have recruited
over 350 patients on the TB ward at Kampala’s
main hospital, and aim to recruit 500 in all.
Initial results suggest that around 12 per cent 
of patients who previously had received treatment
now have multidrug-resistant TB (MDR-TB).
Although this is not as high as in the pilot study, 
it is still of concern. “These individuals are
transmitting multidrug-resistant strains to other
patients and health workers within the hospital and
often take the disease back to their communities,”
says Edward Jones, project coordinator.
Another aim of the project is to come up with 
new and faster ways to identify drug-resistant
strains. “Currently, there is no routine testing for
multidrug-resistant tuberculosis in Uganda,” says
project member Ruth McNerney of the London
School of Hygiene and Tropical Medicine. If these
patients can be identified quickly, they could be
isolated in an attempt to contain transmission 
and different drugs can be tried. Dr McNerney 
is exploring several ways to speed up the process 
of diagnosis. Molecular techniques, for example,
could produce a result in a matter of days rather
than months. 
However, these advances in diagnosis have
created a profound need. “We feel the ethical
obligation to provide treatment to drug-resistant
tuberculosis cases identified in the context of 
our research,” says Dr Ellner. If further work can
come up with an affordable and effective treatment,
the Ugandans should have a system in place 
to prevent the explosion of MDR-TB strains.
Dr Henry Nicholls is a freelance writer based in London, UK.
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Rapid diagnosis and new drugs
would make a huge difference
«
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The Gambia
Unlike the situation in African countries such as
Senegal and Nigeria, many bacteria in the small West
African country of The Gambia show surprisingly low
rates of resistance to antibiotics. Although the reasons
are not clear, Dr Richard Adegbola at the UK Medical
Research Council Laboratories in Banjul suggests that
the low rates are due to control of and reduced access
to drugs. “There is more control of how drugs get 
in and out of the country, and the management of
drugs is very interesting compared to other countries,”
he says. “Every child has a healthcare card that
records every visit to the hospital and the antibiotics
they have been prescribed. But access to antibiotics
can be variable: as you move towards the east into 
the provinces, there are district hospitals that have 
few drugs. So there is less use, which may discourage 
the emergence of resistance.” 
A study by Dr Adegbola and colleagues, aimed at
checking the level of antimicrobial activity in urine before
presentation at hospital, found that only 7 per cent 
of Gambian children under five had taken antibiotics. 
“This is very low,” he points out. “If you did this study 
in Bangladesh or China, say, it would be 80–90 per
cent. Cheap drugs such as chloramphenicol still have
their place in The Gambia.”
For S. pneumoniae, the bacterial pathogen that kills
the most Gambian children, resistance to penicillin 
is almost unknown, whereas neighbouring countries
show over 20 per cent resistance and many other
countries have rates that top 50 per cent. Even so,
resistance to chloramphenicol (about 8 per cent) 
is beginning to emerge, and in vitro resistance 
to cotrimoxazole (trimethoprim-sulfamethoxazole) 
is already over 80 per cent. 
Events in neighbouring countries have also had an
effect on antibiotic resistance in The Gambia. “Until
about five years ago, tetracycline was still used in The
Gambia to treat gonorrhoea, but it has been useless
for well over 15 years in countries like Nigeria because
the bacteria are highly resistant,” says Dr Adegbola.
“Then there were crises in neighbouring countries, 
an influx of people into The Gambia, and we saw a
sudden rise in resistance to pencillin and tetracycline.
These drugs are now virtually useless in the treatment
of this disease.” 
Vaccines
With the power of antibiotics under threat, might new
vaccines be the answer? The introduction into The
Gambia of a vaccine against Haemophilus influenzae
type B shows how effective they can be: the vaccine
was introduced in 1997 and the bacterium, previously 
a major cause of pneumonia and meningitis, has now
all but disappeared from the country. Between 2000
and 2004, Dr Adegbola and colleagues (led by
Professor Felicity Cutts) trialled an S. pneumoniae
vaccine that not only was effective in preventing
pneumonia, but also reduced the number of deaths
and hospital admissions in general. “Finding that the
number of deaths and hospital admissions can be
reduced this much can make a big difference with a
government when you are trying to introduce a vaccine
in Africa,” he points out. 
In Vietnam, the Hospital for Tropical Diseases and 
the Oxford University Clinical Research Unit have been
funded through a Wellcome Trust Technology Transfer
grant that was awarded to Microscience Ltd to trial a
typhoid vaccine. “Currently available typhoid vaccines
give short-lived protection, are expensive, or require
four doses orally,” says Dr Farrar. “We’re about to
start phase 2 and phase 3 trials of this new one-dose
oral vaccine.”
Dr Jeremy Farrar is Director of the Wellcome Trust-funded Oxford
University Clinical Research Unit, Hospital for Tropical Diseases,
Ho Chi Minh City, Vietnam. Dr Richard Adegbola is Head 
of Bacterial Diseases Research Programme at the UK MRC
Laboratories, Banjul, The Gambia.
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Walk into a local pharmacy in Vietnam, and you can
buy antibiotics. Walk along a street in Lagos in Nigeria
or Accra in Ghana, and hawkers will try to sell you
cigarettes, sweets, penicillin, ampicillin and cepha-
losporins. In these and many other countries, antibiotics
are uncontrolled and unregulated – easy to get and
easy to misuse. With such wide availability, it is not
surprising that the prevalence of bacteria resistant 
to one or more antibiotics has increased in many
developing countries. 
Even so, when access to drugs is easier than access
to doctors, or when people may be able to pay for
one but not both, the issue might not be quite so
straightforward. As Dr Jeremy Farrar, Director of the
Oxford University Clinical Research Unit in Ho Chi
Minh City, Vietnam, points out: “When antibiotics are
unregulated, you clearly get big problems with drug
resistance. But we should not forget there may be
benefits of easy access – people may be treated
sooner. We need a greater understanding of anti-
microbial resistance, and in working out how to deal
with this problem we need to appreciate we live 
in the real world where unregulated use is the norm 
and unlikely to change. New imaginative strategies 
to prevent the further spread of resistance are required
as there are few if any new and affordable antibiotics
on the way. In some diseases there is certainly the
possibility of complete resistance developing and 
a return to the pre-antibiotic era.”
Vietnam
Resistance to antibiotics is at worrying levels for 
three bacteria that Dr Farrar picks out as having the
most impact on Vietnam’s healthcare: Streptococcus
pneumoniae, Mycobacterium tuberculosis and
Salmonella typhi. The first of these, often termed the
pneumococcus, causes the most common kind of
bacterial pneumonia and can invade the bloodstream
(bacteraemia) or the tissues and fluids surrounding the
brain and spinal cord (meningitis). According to the 
World Health Organization, pneumococcal pneumonia
and meningitis are responsible for about 1.6 million
deaths each year. 
“Of community-acquired pneumonias that lead to
death, the pneumococcus is probably the number 1
bacterium, and resistance is a highly significant
problem,” says Dr Farrar. “We found that 60–70 per
cent of bacteria carried by people living in urban parts
of Vietnam are resistant to pencillin; resistance to third-
generation cephalosporins is lower but increasing 
and these patterns are now emerging in bacteria 
that cause invasive disease such as pneumonia and
meningitis. The situation is getting worse, and Vietnam
is certainly one of the countries with a major problem.”
Tuberculosis is a massive problem in Vietnam. 
The country has one of the highest incidence rates 
in the world, despite a well-implemented treatment
programme. “In the urban centres, the rates of TB 
are as high as anywhere in the world,” says Dr Farrar.
“There are also very high rates of resistance to one
drug and, worryingly, to multiple drugs.” Although 
TB rates are higher in people with HIV, the incidence of
the virus is still relatively low in Vietnam, around 1 per
cent, which is much lower than in sub-Saharan Africa. 
In Ho Chi Minh City, improvements in sanitation have
led to marked reductions in typhoid, but in the Mekong
delta, home to about 30 million people, the disease 
is still a major problem: incidence rates there are about
200 per 100 000 people. “Asia has the most resistant
Salmonella typhi [the bacterium that causes typhoid
fever] in the world, with major outbreaks in the Central
Asian Republics, and ongoing endemic disease in both
South and South-east Asia,” says Dr Farrar. “Typhoid 
is not as big a disease as tuberculosis or pneumonia,
but treatment is very difficult – 95 per cent of isolates
in Vietnam are resistant to all first- and second-line
antibiotics. All cheap antibiotics are of no value at all;
even the two drugs that do work, don’t work
particularly well and they are very expensive.”
Antibiotic resistance in developing countries
VIETNAM AND THE GAMBIA
Antibiotic-resistant bacteria present huge challenges to healthcare in
developing countries, as Jeremy Farrar and Richard Adegbola describe.
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Two years ago, Sir Liam Donaldson, the Chief Medical
Officer, ordered every NHS trust to appoint a director 
of infection control with responsibility for cutting 
deaths and illness caused by superbugs. Last 
year, the National Audit Office (NAO) launched an
investigation and found rates of infection still rising. 
It criticised the NHS for failing to implement many 
of the recommendations it had made four years earlier 
and called for a more robust approach to antibiotic
prescribing and hospital hygiene. 
One thing distinguished the NAO report from most
pronouncements by politicians. It acknowledged how
intractable the problem of tackling hospital infections
is, estimating just 15 per cent might be preventable. 
The best defences against the bacteria are frequent
handwashing, aseptic techniques and minimising 
use of intravenous lines and catheters, which provide
access for bacteria. Hiring more cleaners and getting
them to mop more thoroughly, desirable as that is for
other reasons, has little effect. Yet this is the solution
favoured by politicians and the press.
There are grounds for hope. The Dutch successfully
reduced their MRSA rate by implementing a policy 
of ‘search and destroy’, which involved screening
patients for the infection and isolating those found 
to be positive in single rooms in modern hospitals. 
To do the same here will be harder because MRSA
rates are higher and the pressure on beds greater. 
We should have acted as the Dutch did, in the early
1990s, when infection rates were still low. 
For one thing, however, we can be grateful. The 
political spotlight that has been shone on MRSA has
given new impetus to the drive to tackle it. Success 
is long overdue. Superbugs may harm far fewer people
than, say, heart disease, but patients have a right to
expect they will get better – not sicker – when they 
go into hospital.
Jeremy Laurance is Health Editor at the Independent.
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There are two ways to launch a biological assault
on the human race. The first is to evolve a lethal
bacterium or virus against which we have no defence.
AIDS, Ebola and Marburg’s disease are examples
caused by toxic organisms that have cut a swath
through humanity and spread fear and panic. 
Less feared but just as deadly are organisms that have
found a way round our defences by evolving protection
against the antibiotic drugs we use to destroy them. 
In evading destruction they survive to multiply, infect
and ultimately overwhelm us. It is their indestructibility,
rather than their toxicity, that makes them lethal. 
The collective blindness the world has shown to the
growth of these drug-resistant bacteria is a matter 
of immense concern. We have seen the consequences
in the UK with outbreaks of methicillin-resistant
Staphylococcus aureus (MRSA) that have closed
hospital wards, caused extensive suffering to patients
and a rising death toll. Deaths from MRSA almost
doubled from 487 in 1999 to 955 in 2003.
Those in the know have long warned that we are
heading for a public health disaster. So the high profile
given to MRSA by politicians of all parties should have
been welcome. The Conservatives led the charge 
with their demand for cleaner hospitals, and Labour
responded with new pledges and new targets.
Cynics will question why the problem of hospital 
infections, which is decades old, should have seized
politicians and the public now. Opportunism is the 
simple answer. In an election year, with little separating
the parties on health policy, the chant of ‘cleaner 
hospitals’ proved an easy slogan with which the 
Conservatives could attack the Government. 
It suited the media, too. “NHS killer bug shock”, 
the Sun screamed in a typical front-page headline on
22 March 2005, above an account of an investigation 
into MRSA levels in one hospital. It was a scare story 
of the kind newspaper editors love: it was simple to
understand and it offered another stick – other than
long waiting lists (which are coming down) – with which
to beat the NHS. 
But there was justification, too. The UK’s record 
on MRSA is undeniably poor, with one of the highest
infection rates in Europe. At the time of writing, 
the most recent figures show that there were 3519
bloodstream infections with MRSA in the six months
from April to September 2004. 
That represented a fall of 6.3 per cent on the same
period a year before, and the Government claimed 
it was a ‘turning point’ when the figures were published
in March. But the Conservatives accused ministers 
of ‘election trickery’ for publishing six-monthly figures
covering last summer rather than the normal 
12-monthly total. The overall figure is expected to rise
in the next six-month period from October 2004 to April
2005 because it covers the winter.
The problem is worst in the south of the country 
and worst in specialist hospitals that treat sicker
patients than general hospitals. The Department of
Health published figures for every NHS trust, showing
some had cut their MRSA rates while others had 
seen big rises. 
To tackle the menace, ministers promised a
crackdown on poor hygiene with hospitals ranked in 
a league table of cleanliness. But it is too little, too late.
MRSA, politics and the press
UNDER THE SPOTLIGHT
Hospital-acquired infections are a hot topic for MPs and the media. 
Jeremy Laurance examines why.
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Producing variants of existing drug classes used 
to be an effective development strategy, but has now
become far more difficult. Drug classes such as beta-
lactams (e.g. penicillins) are, or soon will be, exhausted
– as is the case with quinolones (e.g. ciprofloxacin).
Other established classes such as glycopeptides 
(e.g. vancomycin) and macrolides (e.g. erythromycin)
are also still yielding new analogues, the clinical value
of which remains to be established. 
Newer agents are emerging. Linezolid, the first of a
truly new class, the oxazolidinones, and daptomycin, 
a lipopeptide, both have novel mechanisms of action
and address our current problems with methicillin-
resistant Staphylococcus aureus (MRSA). Other agents
are being developed but none exhibits comprehensive
activity against difficult Gram-negative bacteria such as
Pseudomonas, Acinetobacter and Burkholderia spp.,
which now are untreatable in a proportion of infections.
Finding compounds active against these bacteria has
been a significant challenge for decades.
With our increasing knowledge of the genomes of
human pathogens, target-based research is hailed 
as the most likely technology to reveal new chemical
classes. This cutting-edge technology identifies genes
that are essential to a bacterium and is the starting
point for identifying or designing compounds that can
interfere specifically with the protein products of these
genes. However, multiple difficulties have to be 
overcome to allow progress from ‘essential gene’ 
to development status, and the technology has been
oversold. Consequently, many research groups,
including major companies, have prematurely
withdrawn their activities, leaving us ‘target-rich but
compound-poor’. However, when success comes, 
as it surely will, we will have novel compounds acting
on new antimicrobial targets. One must hope that this
novelty will be marketable.
Concluding comments
With time, bacteria have developed resistance to all
antibacterial agents. A flow of new agents, designed to
circumvent these problems, has up until now provided
the prescriber with alternatives. It is unfortunate that
common bacteria such as staphylococci (MRSA) are
becoming still more problematic and that
Pseudomonas and Acinetobacter spp., for which we
have never had many effective agents, are now more
common and cause untreatable infections. Also, it is
regrettable that this is occurring when pharmaceutical
resources are being directed to other therapy areas.
This impacts not only on the availability of new agents
but also on sponsorship of academic research in this
important area. It is imperative that a formula for
making anti-infectives attractive to the pharmaceutical
industry is re-established; without its expertise new
agents are much less likely to emerge. 
Dr Jeff R Edwards spent his career within the pharmaceutical
industry and now runs a consultancy, JEIC, in north Wales.
When success comes, as it surely
will, we will have novel compounds
acting on new antimicrobial targets
«
«
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The golden age when the pharmaceutical industry
made frequent significant new entries to the anti-
infectives market has ceased. New drugs to tackle
human pathogens have become much harder to find:
many existing drug classes are exhausted or near 
to exhaustion, and genomic-based technologies 
have yet to deliver new agents. This discourages
commercial infection research, as do ever-escalating
regulatory requirements. 
Financial considerations
The pharmaceutical industry has been criticised for
withdrawing from or significantly reducing its infection
research. There is truth in this, but critics often miss
two key points: big pharma has provided every 
antibacterial agent on which the world’s physicians 
rely; and not all companies have pulled back. Among
those still active, AstraZeneca and Johnson & Johnson
both have significant antibacterial research groups 
and also devote effort to tuberculosis research.
Pharmaceutical companies are always under
considerable commercial pressure, and it is important
to note that anti-infectives are not highly profitable. Few
have annual sales greater than US$500 million, while
many therapies for chronic disorders have sales four
to ten times greater. This factor becomes very apparent
within a company when there is competition for core
development resources, which typically will support a
chronic-therapy opportunity. Yet a successful business
should seek to have a balanced portfolio and have
some contingency for a ‘megabrand’ failure; infection
products, particularly those from new chemical series,
can provide that balance.
Taking advantage of the pressures on big pharma,
many small companies requiring more modest
financial returns have emerged. Typically, they have
excellent scientists restricted by lack of finance and,
on occasion, by lack of development experience.
Even so, they may be the future home of anti-infective
research and development. This is exemplified by
Cubist’s in-licensing and developing daptomycin, 
a drug previously shelved by a large company.
Regulatory issues
Regulatory agencies require that sponsors adopt the
highest standards in all studies. Exemplary standards
should not be questioned, but the magnitude of studies
continues to increase. Fortunately, some progress has
been made on the international harmonisation of
requirements. Once toxicological hurdles are passed,
human tolerance and kinetic studies can commence. 
If these progress to therapy trials, the demands are
stringent, exceptionally costly and, for some clinical
indications, almost impossible to meet. This exacting
position for the assessment of known drug classes
already acts as a disincentive to commercial research
and development; one can but speculate about the
caution with which new chemical types will be viewed.
Bugs and drugs
Statements that there are no new drugs and that
resistance is out of control are misleading. More
accurately, there are few new significant agents 
being developed and, while in vitro surveys show 
an increase of less susceptible bacteria, only a small
proportion of patients is infected with untreatable
bacteria. Thus, the current situation is that physicians
have less choice of agents: all of the established
therapies retain significant clinical utility, but we 
should expect this situation to worsen.
The pharmaceutical industry 
and antibiotic development
WHERE ARE THE NEW DRUGS? 
Why is it that when resistance to antibacterial agents is increasing, 
fewer agents are being developed? By Jeff R Edwards.
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“The problem of antibiotic resistance isn’t going to go
away,” says Dr Tim Walsh at the University of Bristol.
“The problem of the ‘MRSA superbug’ is well
documented but there are other bacteria, such as
Pseudomonas aeruginosa and Acinetobacter spp.,
which are multi-resistant and cause serious infections.
Unfortunately, while the problem warrants increasingly
urgent attention, it is attracting less. “The number 
of large pharmaceutical companies working on anti-
infectives has dropped around 60 per cent from ten
years ago,” says Dr Walsh. As patients only take
antibiotics for one or two weeks for serious infections –
unlike other therapies such as anti-depressants, which
are taken on an ongoing basis – it makes less
economic sense for pharmaceutical companies 
to invest in developing them. 
This is not to say that antibiotic development has
stopped altogether. For example, three new anti-
infectives with good activity against MRSA –
daptomycin, linezolid and tigecycline (FDA approved
June 2005) – have been or will be available worldwide.
“Plus there are other drugs in phase 2 and 3 [clinical]
trials, so new treatments for MRSA and bacteria
causing community acquired pneumonia are well
advanced in the pipeline,” says Dr Walsh.
Breaking the Gram-negative barrier
Unlike Gram-positive bacteria, Gram-negatives have 
an additional membrane that water-soluble (hydrophilic)
compounds cannot unconditionally traverse. Drugs
must cross the membrane through porins – channels
that enable nutrients and metabolites to enter the cell.
However, many Gram-negative bacteria, especially
Pseudomonas, Acinetobacter and Enterobacteriaceae,
can shut off some of these porins and prevent foreign
compounds from entering. 
As a result, points out Dr Walsh, although there are
many compounds oriented towards Gram-positive
bacteria such as MRSA on the market, hitherto there 
is nothing available that is purely anti-Gram-negative 
or, at least, has good activity against pan-resistant
Acinetobacter and Pseudomonas spp. 
An answer might lie in an agent produced in our bodies
by Gram-positive bacteria that are considered normal
flora and not harmful. Dr Walsh became interested 
in this possibility after work by Dr Malcolm Gallagher 
at the University of Liverpool on cystic fibrosis patients. 
He found that where antibiotics inhibited normal Gram-
positive flora, there was a growth of the Gram-negative
pathogen Pseudomonas aeruginosa. These virulent
pathogens cause inflammation in the lung in cystic
fibrosis, killing many young adults with the disease. 
“So, in our own bodies, a Gram-positive bacterium
produces a factor that inhibits the growth of Gram-
negative bacteria such as P. aeruginosa, which are
resistant to just about all antibiotics,” says Dr Walsh.
“Such observations go back to the days of Fleming
who found that penicillin on a plate (produced by
Penicillium spp.) inhibits Staphylococcus aureus.” 
The Bristol team found that the factor was produced
by the Gram-positive bacteria Streptococcus mitis,
Streptococcus oralis and Streptococcus mutans,
bacteria that live in the human respiratory tract and
mouth. They then grew a protein ‘soup’ produced 
by  these bacteria and challenged Pseudomonas
bacteria (obtained from samples from people with
cystic fibrosis) to find out what factors – produced 
by the soup – kill the intransigent P. aeruginosa. 
Investigations revealed that S. mitis produces at least
two proteins that inhibit P. aeruginosa: the peptides
RTA1 and RTA2. These have a number of specific
properties that could make them ideal anti-Gram-
negative compounds. First, they are very small and
thus more likely to bypass the immune system (larger
peptides are more likely to elicit an immune response).
Second, both are hydrophilic and soluble at very high
concentrations. And third, importantly, both actively
break open and kill P. aeruginosa. “A lot of drugs
New agents to combat bacterial infections
IN THE PIPELINE
Wellcome Trust-funded researchers are developing anti-infectives against
the two main groups of bacteria: Gram-positive and Gram-negative bacteria.  
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Where to find out more
A selection of internet resources about antibiotic
resistance and healthcare-associated infections. 
Most sites include links to additional resources.
General
Bugs and Drugs on the Web
www.antibioticresistance.org.uk
Alliance for the Prudent Use of Antibiotics
www.tufts.edu/med/apua
History of antibiotics
Witness Seminar 6: Post Penicillin Antibiotics
www.ucl.ac.uk/histmed/witness06.html
UK
Department of Health: Healthcare-associated infection
www.dh.gov.uk/PolicyAndGuidance/HealthAndSocial
CareTopics/HealthcareAcquiredInfection/fs/en
Department of Health: Antimicrobial resistance
www.dh.gov.uk/PolicyAndGuidance/HealthAndSocial
CareTopics/AntimicrobialResistance/fs/en
Health Protection Agency: Antimicrobial resistance
www.hpa.org.uk/infections/topics_az/antimicrobial
_resistance/menu.htm
British Society for Antimicrobial Chemotherapy
www.bsac.org.uk
Hospital Infection Society
www.his.org.uk
Other
European Antimicrobial Resistance 
Surveillance System
www.earss.rivm.nl
US Food and Drug Administration: 
Antibiotic resistance
www.fda.gov/oc/opacom/hottopics/anti_resist.html
For children
The Bug Investigators
www.buginvestigators.co.uk
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prevent the organism from growing, but don’t actively 
kill it,” explains Dr Walsh. “RTA1 and RTA2 punch
holes in P. aeruginosa bacteria, in their membranes.” 
Having isolated RTA1 and RTA2 and determined the
genome region responsible for their production, the
team now aims to modify and maximise the ideal
therapeutic properties of these peptides. “We want to
make them shorter, increase their hydrophilic properties
and make them more active,” says Dr Walsh. “The
smaller one, RTA1, is fantastically active against Gram-
negative bacteria; it’s a molecule well worth pursuing.” 
So far, the team has tested the peptide on only ten
pan-resistant clinical isolates, but aim to examine its
efficacy (and any subsequent derivatives) on disparate
group of around 3000 to 4000 Gram-negative
bacteria. “As with any new drug, we want to see
whether it works, and make sure it isn’t too toxic 
for the patient,” says Dr Walsh. 
On the positive side
Although compounds targeting Gram-positive bacteria
are more readily available than those directed at Gram-
negative bacteria, many Gram-positive bacteria, such 
as MRSA, are becoming resistant to antibiotics,
especially in hospitals.
“There’s a big unmet clinical need for new agents,” 
says Dr Michael Dawson at Novacta Biosystems Ltd 
in Hatfield, Hertfordshire. Dr Dawson originally helped 
to set up the start-up company in Norfolk in 2003, 
to take advantage of technologies for engineering
biosynthetic pathways using molecular biology, in 
order to optimise the therapeutic potential of natural 
products against infection.  
“We’re interested in a molecule that hasn’t been 
used before and has no cross-resistance with other
antibiotics – including vancomycin, which people 
use against MRSA when other antibiotics have 
failed,” he says. The molecule in question, called
mersacidin – meaning, literally, ‘kill MRSA’ – has 
good activity against MRSA as well as other Gram-
positive pathogens. 
Like many antibiotics, mersacidin is made by bacteria 
(in this case, a bacillus) to kill other bacteria competing
with them in the environment. But Dr Dawson points 
out that it has a different mode of action from other
antibiotics. “It kills the microorganism by binding to 
lipid 2, a monomer that builds up the cell wall,” he
explains. Lipid 2 is also a target of vancomycin, but
mersacidin binds to a different part of the molecule.  
Mersacidin was discovered in the early 1990s by the
pharmaceutical company Hoechst, who considered
developing it for its antibacterial activity. At that time,
however, resistance was less of a problem and, 
despite its promising properties, the molecule needed
‘improving’ in some areas to give it a spectrum of
activity. The complex chemistry required for this task
was not then available. 
Researchers at the University of Bonn have since
cloned the pathways in the bacillus bacteria that make
mersacidin, and Novacta Biosystems has developed
and patented methods of manipulating the biosynthetic
apparatus. “We’re using molecular biology technologies
to modify the bacillus organism and get it to make 
lots of variant molecules that can be tested for their
effectiveness against MRSA,” explains Dr Dawson. 
The team aims to test thousands of these variants, 
looking at which pathogens they kill and at which 
concentrations. Although still at the lead improvement
phase at the moment, in two years’ time they hope 
to start conducting phase 1 trials of mersacidin with
human volunteers. 
Dr Tim Walsh at the University of Bristol, UK, and Dr Michael Dawson 
at Novacta Biosystems Ltd in Hatfield, UK, are funded by awards 
from the Wellcome Trust’s Technology Transfer Division. 
